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Abstract 
Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, 
adhesion molecules and signal transduction platforms in a multitude of biological processes. 
As such, integrins are central to the etiology and pathology of many disease states. Therefore, 
pharmacological inhibition of integrins is of great interest for the treatment and prevention of 
disease. In the last two decades several integrin-targeted drugs have made their way into 
clinical use, many others are in clinical trials and still more are showing promise as they ad-
vance through preclinical development. Herein, this review examines and evaluates the var-
ious drugs and compounds targeting integrins and the disease states in which they are im-
plicated. 
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1. Introduction 
Integrins are heterodimeric cell surface receptors 
found in nearly all metazoan cell types, composed of 
non-covalently linked  and  subunits. In mammals, 
eighteen -subunits and eight -subunits have been 
identified to date [1]. From this pool, 24 distinct het-
erodimer  combinations  have  been  observed  in  vivo 
that  confer  cell-to-cell  and  cell-to-ligand  specificity 
relevant to the host cell and the environment in which 
it  functions  [2].  Integrin-mediated  interactions  with 
the  extracellular  matrix  (ECM)  are  required  for  the 
attachment,  cytoskeletal  organization,  mechanosens-
ing, migration, proliferation, differentiation and sur-
vival of cells in the context of a multitude of biological 
processes  including  fertilization,  implantation  and 
embryonic  development,  immune  response,  bone 
resorption  and  platelet  aggregation.  Integrins  also 
function in pathological processes such as inflamma-
tion, wound healing, angiogenesis, and tumor metas-
tasis. In addition, integrin binding has been identified 
as a means of viral entry into cells [3].  
 Integrin mediated cellular adhesion is dynamic 
process that is both indicative of and influenced by 
cell status. Integrins are not constitutively active but 
rather exist in multiple activation states wherein lig-
and binding stability is related to the activation status 
of the receptor. The biodirectional nature of integrin 
mediated signaling allows both extra- and intracellu-
lar cues to regulate activation [4] (Fig. 1). Extracellular 
factors  that  influence  integrin  activation  are  ligand 
binding,  divalent  cation  concentration,  chemokine 
signaling and mechanical stress. Intracellular signal-




of integrin tails are also capable of activating the high 
affinity state. Intracellular signals that result in integ-
rin activation are referred to as ‘inside-out’ signaling 
events.  
Integrin ligation via cell-to-cell and cell-to-matrix 
contacts transduces intracellular signaling events in a 
process called ‘outside-in’ signaling (Fig. 2). The in-
tegrin tails have no intrinsic kinase activity but rather 
serve as a site for the docking of various kinases and 
related  adaptor  proteins  that  comprise  focal  adhe-
sions.  The  -tail  is  the  primary  docking  site  in  the 
formation  of  focal  adhesions,  but  the  alpha  tail  in 
some cases may also serve as a signaling scaffold for 
calcium dependent signaling events. Signals emanat-
ing from focal adhesions have been shown to promote 
survival, differentiation and proliferation [5]. In the 
absence of integrin ligation, these processes are abro-
gated therefore pharmacological inhibition of integrin 
ligation is of great interest for the therapy of numer-
ous diseases resulting from abberant integrin medi-
ated signaling.  
Through cell-cell and cell-ECM contacts, integ-
rins  behave  as  mechanosensors,  bi-directionally 
transducing information both into and out of the cell, 
directing  the strength, stability and growth of focal 
adhesions  to  promote  cell  adhesion,  spreading  and 
motility  (Fig.  3).  Talin  binding  to  activated  integrin 
-tails  promotes  cytoskeletal  organization  via  the 
crosslinking of both vinculin and actin. Association of 
talin with vinculin promotes focal adhesion growth, 
while crosslinking of viculin and actin through talin 
provides stable adhesion [5]. Disruption of focal ad-
hesions prevents integrin mediated cell adhesion and 
impaired  cell  motility  and  migration.  Prolonged  in-
tegrin inhibition in adhesion dependent cells results 
in anoikis, apoptotic cell death due to ECM depriva-
tion [6].  
By integrating and transducing information both 
into and out of the cell, integrins mediate cell locali-
zation,  shape,  spreading  and  motility  and  thus  are 
critical determinants of both health and disease. In-
tegrins have been implicated in the pathogenesis of 
inflammatory  disease,  platelet  aggregation,  tumor 
progression as well as osteoporosis and macular de-
generation. The role of integrins in pathological con-
ditions coupled with their ‘druggability’ by means of 




Figure 1. Integrin “Inside-out” signaling promotes integrin activation and heightens ligand affinity. External activating stimuli 
such as integrin or selectin ligation or cytokine binding to G-protein coupled receptors triggers intracellular signaling cas-
cades that converge on integrin -subunit tails. The activating signals induce conformational changes in the integrin tails that 
facilitate the docking of focal adhesion components such as Talin. The conformational changes in the tail region are 





Figure  2. Integrin “Outside-in” signaling governs cellular processes. Ligand binding serves as the initiation point for 
transduction of intracellular signaling cascades that regulate a multitude of biological processes. Figure adapted from ref-
erence 5 with permission.  
 
Figure 3. Integrins are the site of focal adhesions. Integrin ligation promotes receptor clustering and the formation of focal 
adhesions. Talin forms the initial contacts between integrin -tails and the actin cytoskeleton. Vinculin crosslinks with Talin 
and actin to strengthen focal adhesions promoting focal adhesion growth. -actinin can interact with integrin -tails, vinculin, 
talin and actin to further reinforce crosslinking of the cytoskeleton. ILK associates with actin through its binding partner 
parvin creating a core scaffold for focal adhesion formation. Focal adhesion kinase (FAK) is involved in focal adhesion sta-
bilization and turnover likely through post-translational modification of focal adhesion components. 




2. Integrin structure, ligand binding and ac-
tivation 
The structural classification of integrins is based 
on the presence or absence of an extracellular A-type 
domain  in  the  -  subunit.  A-type  domain  integrins 
contain  an  ~180  amino  acid  metal  ion  coordinating 
insert that is required for ligand binding [7]. Within 
this domain a five amino acid motif termed the metal 
ion dependent adhesion site (MIDAS) acts to coordi-
nate  a  divalent  metal  ion.  Ligand  binding  places  a 
glutamate  residue  within  MIDAS  to  participate  in 
metal coordination [8]. Integrins  lacking the A-type 
domain  contain  a  similar  domain  within  the 
-subunit, termed the A domain. Ligand binding to 
A  integrins  occurs  through  a  divalent  cation  de-
pendent site that requires glutamate or a similar acidic 
residue within the ligand to stabilize the metal coor-
dination [9]. In contrast to the A-type domain, in the 
absence of ligand a proximal glutamate can serve as 
an alternate coordinating residue.  
Information  regarding  integrin  structure  has 
been obtained by NMR, electron microscopy and ro-
tary  shadowing  techniques.  High  resolution  crystal 
structures are the method of choice for structural de-
termination  for  the  development  of  therapeutics. 
High-resolution  crystal  structures  of  membrane 
spanning proteins are a challenge to obtain due to the 
fluid nature of most biological membranes. For this 
reason there are no entire integrin crystal structures. 
The  most  complete  information  regarding  integrin 
atomic structure to date has been derived from the 
crystal  structures  of  the  ectodomains  of  v3  and 
IIb3  in  both  the  presence  and  absence  of  ligand 
[10-12].  Due  to  the  homology  observed  between   
subunits and to a lesser degree,  subunits, and sup-
porting NMR and crystal structure data it can be con-
cluded that most integrins adopt a similar structural 
conformation to those seen in the v3, IIb3 crystal 
structures.  
The    and    integrin  subunits  form  a 
non-covalently associated dimer, each consisting of an 
NH2-terminal extracellular domain, a transmembrane 
domain (TM) and a cytoplasmic tail. The extracellular 
domain  protrudes  from  the  cell  surface  to  interact 
with and bind, in a divalent cation-dependent man-
ner, ligands of the extracellular matrix. The domains 
that comprise the extracellular portion of v3 adopt 
a conformation that is often likened to a head and two 
tails.  The  transmembrane  domain  traverses  the  cell 
membrane linking the extracellular domain and cyto-
plasmic tail. The cytoplasmic tails act as adaptor pro-
teins for intracellular signaling molecules as well as a 
scaffold for the formation of focal adhesions and in-
teractions with the cytoskeleton.  
Each individual integrin pair recognizes its own 
specific set of ECM proteins. There is to some extent 
overlap between integrins in their ligand recognition, 
as they generally recognize a single sequence motif 
common  among  matrix  components.  Based  on  the 
v3  crystal  stucture,  the  head-piece  is  the  site  of 
ligand binding and is formed by the -propeller of the 
v subunit and the hybrid and A-domains of 3. The 
ECM ligand binding site appears to be formed more 
or  less  equally  by  both  subunits  (Fig.  4).  Ligand 
recognition in the v3 integrin is through the argi-
nine-glycine-aspartate (RGD) sequence of ECM mol-
ecules such as vitronectin and fibronectin (Fig. 5). The 
arginine  residue  forms  salt  bridges  with  aspartate 
residues within the -propeller while the carboxylate 
group  within  the  aspartate  residue  of  the  RGD  se-
quence forms a series of polar interactions in the A 
domain, and the glycine residue appears to form hy-
drophobic contacts solely with the v subunit.  
 The seven-bladed, -propeller is formed by the 
arrangement of 4-stranded anti-parallel -sheets. The 
radial arrangement of the -sheets forms a channel or 
cup-like structure composed mainly of aromatic res-
idues in a consensus sequence termed the cage motif. 
Within the -propeller are 4 Ca2+ coordination sites 
that  may  impart  structural  rigidity  in  the  contacts 
between domains. The A-domain is a six stranded 
beta sheet flanked by eight alpha helices. In these and 
other crystal structures, the integrin appears in a bent 
or folded over conformation that is believed to repre-
sent the low affinity state. In addition to the 4 Ca2+ 
binding sites, another metal ion dependent adhesion 
site exists is the A domain which mediates a magne-
sium ion necessary for ligand binding.  
Structural changes caused by ligand binding ac-
tivate outside-in signaling. ECM binding causes dis-
placement of residues within the ligand binding site 
that promote further structural rearrangements of the 
ectodomain that ultimately cause the separation of the 
intracellular tails [5]. This spatial separation facilitates 
the formation of focal adhesions and signaling com-
plexes required for downstream effects. Two models 
of integrin activation have emerged based on NMR 
and  crystal  structure  data,  the  switchblade  and 
deadbolt  models  [13-14].  Both  models  propose  that 
conformational  rearrangements  activate  integrin 
binding  and  increase  infinity.  In  the  switchblade 
model,  movements  within  the  transmembrane  re-
gions of the dimer promote extension of the extracel-
lular domain leading to increased ligand avidity. The 




tains its bent conformation but allows movement of 
the transmembrane domain in a manner that opens 
the ligand binding site to heighten receptor avidity. 
 
 
Figure 4. CycloRGDFV bound to v3 (RCSB code: 1L5G). Metal ions Mn
2+ are depicted as spheres. 
 
Figure 5. Ligand binding site of v3 integrin (RCSB code: 1L5G) in complex with RGD peptide showing close contact 
residues of cycloRGDFV at the integrin dimer interface. 
 




3. Approaches to integrin targeting  
 The  functionality  of  integrins  is  dependent  on 
activation, ligand binding, focal adhesion formation 
and cytoskeletal contacts.  Inhibition of any  of these 
events  abrogates  integrin  regulated  functions  and 
thus  each  comprise  a  valid  pharmacological  target. 
Based on a survey of current anti-integrin therapeu-
tics and preclinical literature the  most common ap-
proach to integrin antagonism involves targeting at or 
near the receptor binding site but knowledge of in-
tegrin activation and downstream signaling suggests 
that alternate approaches are possible.  
Targeting  the  ligand  binding  site  has  been  ac-
complished through the use of antibodies, cyclic pep-
tides, disintegrins, peptidomimetics and small mole-
cules  antagonists.  These  compounds  are  meant  to 
bind the targeted integrin in a manner similar to the 
endogenous  ligand  thereby  displacing  it  and  pre-
venting integrin ligation. This method of antagonism 
has  been  widely  utilized  for  several  reasons.  The 
paucity of informative structural data regarding the 
relevant  integrins  allows  the  rational  design  of  an-
tagonists based on known ligands. In addition, extra-
cellular regions are preferable protein targets as they 
circumvent the problems associated with intracellular 
drug  delivery  such  as  lysosomal  degradation  and 
activation of drug efflux pumps. In addition the ex-
tracellular  domains  are  the  only  regions  accessible 
using antibody-based therapeutics, which constitute a 
large  portion  of  the  antagonists  in  clinical  use  and 
under  development.  Finally,  the  majority  of  high 
throughput  screening  methods  utilize  solid  phase 
receptor  binding  assays  that  screen  for  compounds 
that  are  able  to  inhibit  ligand  binding  and  thus  by 
design favor the identification of compounds showing 
affinity to the ligand binding site. A similar method of 
antagonism involves the binding of molecules or an-
tibodies  in  close  proximity  to  the  natural  ligand 
binding site. This strategy provides steric hindrance of 
the ligand binding site such that endogenous binding 
site is obscured and ligand binding is prevented.  
Proposed  crystallographic  and  NMR-based 
models maintain integrin activation is dependent on 
global  structural  rearrangements.  Targeting  sites  of 
allosteric control may represent an alternate means by 
which  to  antagonize  integrin  function.  Our  current 
understanding  of  integrin  activation  postulates  that 
both extra- and intra-cellular cues can propagate sig-
naling  cascades  that  act  on  intracellular  portions  of 
integrins  to  activate  inside-out  signaling.  The  pres-
ence of metal ion dependent adhesion sites (MIDAS) 
and  calcium  coordination  sites  further  supports  the 
assertion that function is dependent on specific con-
formational  arrangements.  Therefore  dependence  of 
activation on conformational arrangements suggests 
that sites of allosteric control exist either intra- or ex-
tracellularly  on  integrins.  This  is  significant  for  the 
design of anti-platelet integrin antagonists for which 
conformational changes induced by ligand mimetics 
have been proposed to lead to the adverse effects as-
sociated with paradoxical platelet activation.  
Targeting  the  intracellular  ‘tails’  of  integrins 
represents  another  underutilized  therapeutic  ap-
proach to antagonism. Focal adhesion formation oc-
curs at integrin tails and is the earliest intracellular 
event following ECM ligation. The formation of the 
signaling platform at this level impinges on cellular 
fate.  Post-translational  modification  of  integrin  tails 
determines the composition of the signaling platform 
which ultimately regulates the nature of the signals 
transduced  downstream.  Pharmacological  modifica-
tion  of  integrin  tails  therefore  has  the  potential  of 
regulation the nature and extent of integrin signaling 
to mediate the potential outcome  of ligand engage-
ment.  Integrin  tails  are  also  extensively  crosslinked 
with the actin cytoskeleton via interactions with talin 
and vinculin. Pharmaceutical inhibition of cytoskele-
tal organization can inhibit cell proliferation and mi-
gration for the treatment of inflammatory disorders or 
inhibition of tumor growth.  
Integrin  targeting  therapeutics  come  in  many 
forms, each type having its own inherent advantages 
and limitations. In addition the approach to integrin 
specific drug design is dependent on multiple factors 
including  the  expected  clinical  application  and  the 
availability of reliable structural information. In this 
review we will primarily discuss three types of integ-
rin  therapeutics,  targeted  antibodies,  peptide-based 
drugs and small molecule, peptidomimetics.  
Based  on  their  status  in  current  clinical  devel-
opment, therapeutic antibodies (Fig. 6A) are the most 
abundant  integrin  targeting  drugs.  Therapeutic  in-
tegrin-targeted  antibodies  are  currently  under  pre-
clinical  development  and  clinical  evaluation  for  the 
treatment  of  cancer,  multiple  sclerosis,  Crohn’s  dis-
ease, psoriasis, rheumatoid arthritis and acute coro-
nary syndromes. Antibodies are advantageous in that 
they exhibit very high target specificity and affinity, 
limiting toxicities relating to ‘off-target’ effects. From 
a drug design standpoint antibodies are more easily 
developed because high-resolution structural data is 
not  necessary  for  therapeutic  development.  Once  a 
function-blocking  antibody  is  identified  it  can  be 
modified to increase specificity and binding affinity 
and lower immunogenicity. Antibodies can have long 
circulation lifetimes compared to small molecule and 




therapy, that depending on the intended application 
may or may not be advantageous. The disadvantages 
associated  with  antibody  therapeutics  are  the  high 
cost of production, the need for intravenous admin-
istration in a clinical setting, and the propensity for 
host immunogenicity and infusion reactions.  
 
 
Figure 6. Examples of integrin antagonists (A) therapeutic 
antibody (B) cyclic peptide (C) small molecule antagonist. 
 
Peptide-based drugs (Fig. 6B) represent another 
class  of  drugs  designed  to  target  integrins.  These 
drugs incorporate peptide sequences similar to ligand 
recognition sequences in endogenous integrin ligands 
and thus compete for the ligand binding site within 
integrins. This type of drug is advantageous for drug 
design as most of the endogenous ligands and their 
recognition sequences have been determined for each 
integrin pair. Peptide-based integrin targeting drugs 
have  moderate  to  high  target  affinity  but  may  lack 
specificity, as the same ligand recognition sequences 
are  shared  amongst  many  integrins.  Varying  the 
identity of specific peptides flanking the recognition 
sequence  has  been  demonstrated  to  impart  greater 
specificity between integrins by exploiting the subtle 
variations in topology amongst the dimer interfaces. 
Steric constraints imparted by peptide cyclization can 
also improve  specificity and protect against proteo-
lytic cleavage in vivo. The addition of D-amino acids 
is  another  means  of  prolonging  circulation  half-life 
and  protecting  against  hydrolysis.  Peptide-based 
drugs have additional disadvantages such as requir-
ing  injection  or  intravenous  administration,  high 
production cost, and limited stability.  
Small molecule compounds (Fig.  6C) represent 
another class of integrin targeting drugs. Small mol-
ecule drugs are synthetic compounds with low mo-
lecular  weight  having  favorable  biopharmaceutical 
properties.  They  are  readily  synthesized,  are  less 
costly  to  manufacture  than  antibody  and  protein 
based  drugs,  have  better  stability  profiles,  and  in 
many cases can be administered orally. Despite these 
advantages  the  development  of  small  molecule  an-
tagonists  that  target  integrins  remains  a  challenge. 
Several methods have been applied for the develop-
ment of small molecule integrin antagonists, includ-
ing  pharmacophore  based  modeling,  bioisosteric 
substitution  and  high-throughput  library  screening. 
Most compounds in the clinic and under development 
retain structural features that preserve the molecular 
interactions  observed  between  the  integrin  and  its 
native ligand. These molecules tend to be zwitterionic 
in nature and generally encounter limitations in bio-
availability,  serum  protein  binding  and  integrin  se-
lectivity.  
4. IIb3 integrin  
The IIb3 integrin is comprised of a 136 kDa 
IIb  subunit  non-covalently  associated  with  the 
92kDa 3 subunit. The IIb3 integrin exists in vari-
ous  states  of  activation.  Activated,  ligand  occupied 
and resting states have been demonstrated. Activating 
signals are required for ligand binding and lead to a 
conformational change in IIb3 integrin that increase 
ligand  affinity,  receptor  clustering  leading  to  in-
creased ligand avidity. IIb3 integrin recognizes two 
separate  consensus  sequences,  the  argi-
nine-glycine-aspartic acid (RGD) sequence [15] in fi-
brinogen, fibronectin, and Von Willebrand Factor and 
the  lysine-glutamine-alanine-glycine-aspartate-valine 
sequence  found  in  the  gamma  chain  of  fibrinogen 
[16-17]. As with v3 integrin, coordination of Ca2+ 
ions within MIDAS and ADMIDAS are required for 
ligand binding. 
IIb3 integrin (GPIIa/IIIb) is highly expressed 
on the surface of platelets and to a lesser degree, on 
megakaryocytes  [18].  IIb3  integrin  comprises  ap-
proximately 80% of the total surface proteins found 
on platelets. Engagement of this integrin is induced by 
platelet activation and represents the final common 
pathway in blood coagulation (Fig. 7). Under normal 
conditions integrin IIb3 is maintained in the inac-
tivated  state.  Soluble  factors  in  the  blood  such  as 
thrombin, ADP and thromboxane A2 bind their re-
spective platelet receptors to activate inside-out sig-
naling pathways that cause conformational changes in 
IIb3 integrin [18]. Changes in conformation lead to 
modulation  of  ligand  binding  affinity  and  promote 




ceptor affinity and avidity promote platelet aggrega-
tion and clot formation through increased cell-to-cell 
contacts and cell-matrix contacts mediated by integrin 
IIb3. Aberrant platelet aggregation or thrombosis is 
central  to  the  pathophysiology  of  multiple  Acute 
Coronary  Syndromes  (ACS),  unstable  angina,  is-
chemic  stroke  and  sickle  cell  anemia.  Inhibition  of 
IIb3  prevents  platelet  aggregation  and  therefore 
has shown efficacy in the prevention of thrombosis for 
the treatment of ACS.  
 
 
Figure 7. Mechanisms of platelet activation. Binding of secreted factors to cognate ligands promotes platelet activation 
leading to αIIbβ3 activation. Activation of αIIbβ3 promotes integrin clustering and binding of fibrinogen and von Willebrand 
Factor leading to platelet aggregation and thrombus formation. 
 
 
IIb3 integrin antagonists in Percutaneous Cardiac 
Intervention, Acute Coronary Syndromes and Myocardial 
Infarction.  Currently,  there  are  three  FDA  approved 
therapeutics  targeting  IIb3  integrin,  Abciximab, 
eptifibatide and tirofiban. These therapeutics are di-
rected against IIb3 integrin and act in the preven-
tion of platelet aggregation. They are utilized during 
stent  placement  and  other  percutaneous  coronary 
intervention  (PCI)  procedures  for  the  treatment  of 
both ST-elevated myocardial infarction (STEMI) and 
non ST-elevated myocardial infarction (nSTEMI). All 
three  antagonists  have  been  extensively  studied  in 
large  randomized,  placebo  controlled  clinical  trials 
and  demonstrated  advantages  over  previous  an-
ti-platelet treatment modalities such as aspirin and the 
thienopyridines  in  preventing  thrombosis  and  mor-
tality. Although all three compounds act at the level of 
integrin IIb3 to prevent thrombus formation, they 
represent separate classes of drug and thus differ in 
their  pharmacokinetic  and  pharmacodynamic  prop-
erties. The variations between each of these antago-
nists determine the extent of their utility in the treat-
ment  of  various  ACS.  The  clinical  success  of  these 
agents  in  the  prevention  of  platelet  adhesion  have 
prompted  evaluation  for  the  treatment  of  disorders 
and disease states in which abberant platelet aggre-
gation is central to the pathology, such as ischemic 
stroke and sickle cell disease.  
Abciximab. Abciximab  (ReoPro,  c7E3)  was  ap-
proved for use by the U.S. Food and Drug Admin-
istration for perioperative use in percutaneous coro-




tagonist to be approved for clinical use. Abciximab is 
the  Fab  fragment  of  a  monoclonal,  chimeric 
mouse-human antibody with specificity towards the 
IIb3  integrin  as  well  as  the  v3  [19]  and  M2 
(MAC-1) integrins [20]. The platelet integrin (IIb3) 
epitope for Abciximab has been identified as a region 
within  the  -chain  proximal  to  the  RGD-sequence 
binding site and the secondary fibrinogen binding site 
[20].  Hence  Abciximab  inhibits  platelet  aggregation 
via steric hindrance of ligand binding.  
For  use  in  PCI,  the  treatment  of  MI  and  ACS, 
Abciximab is administered parenterally and the un-
bound fraction undergoes rapid proteolytic cleavage 
in the bloodstream. Due to short plasma half-life it is 
administered as a single bolus followed by continuous 
infusion  over  a  period  of  12-96  hours.  The  plasma 
concentrations  drop  rapidly  upon  discontinuation, 
the first phase half-life is close to 10 minutes and the 
second  phase  half-life  is  about  30  minutes  due  to 
rapid  receptor  occupancy.  A  slow  decline  in  drug 
concentration  results  in  an  overall  half-life  of  ap-
proximately  7h  and  continued  low-grade  receptor 
blockade has been  noted for periods up to 10 days 
post infusion [21]. Abciximab is recommended for the 
treatment of both nSTEMI and STEMI [22]. 
Eptifibatide.   Eptifibatide (Fig. 8) is a synthetic cy-
clic  heptapeptide  derived  from  barbourin,  a  snake 
venom disintigrin. Modifying the KGD sequence  of 
barbourin, to homo-ArgGD and cyclization by intro-
duction of a disulfide bridge produced a competitive 
inhibitor  that  shows  high  selectivity  for  IIb3  at 
lower  concentrations  than  the  linear  peptide  [23]. 
Eptifibatide has low binding affinity and rapidly dis-
sociates  from  IIb3  in  circulation,  such  that  by  4 
hours post administration, platelet binding ability is 
restored. Dosing is usually administered parenterally 
as a single or double bolus in combination with con-
tinuous  infusion.  The  plasma  half  life  is  approxi-
mately 2.5 h and the drug is cleared mainly by the 
kidneys  as  epitifabitide,  deamidated  eptifabitde  or 
other  polar  metabolites.  Due  to  the  extensive  renal 
clearance,  dosing  modifications  must  be  considered 
for renal impaired patients [24]. 
Tirofiban.  Tirofiban  (Fig.  8)  is  a  non-peptide, 
small molecule RGD-mimetic antagonist specific for 
IIb3  integrin.  Tirofiban  was  developed  through 
sequential  bioisosteric  substitutions  of  a  candidate 
molecule pharmacophore chosen to approximate the 
bond  distances  observed  between  the  carboxy  and 
amino portions of the RGD-scaffold. This produced a 
small  molecule,  tyrosine-derivative  with  increased 
potency and selectivity for IIb3. Tirofiban prevents 
fibrinogen binding and platelet aggregation in vitro 
by 50% at concentrations of 5 and 11 nM, respectively 
[25]. Tirofiban is administered intravenously. As with 
eptifibatide,  this  small  molecule  competes  with  fi-
brinogen  and  von  Wilebrand  Factor  for  the 
RGD-sequence  binding  pocket  of  platelet  integrin 
IIb3. It binds with higher affinity than eptifibatide 
but  has  a  comparable  volume  of  distribution  and 
plasma  half-life.  Tirofiban  is  not  highly  bound  to 
plasma in the bloodstream and the volume of distri-
bution  at  steady  state  suggests  that  a  large  portion 
distributes  within  the  extracellular  space.  Tirofiban 
has a plasma half-life of 1.5-2h and is excreted mostly 
as unchanged compound in the urine and feces. Renal 
insufficient patients require dose reductions and se-
vere renal failure prohibits use. Hepatic failure does 
not require dose adjustment [26]. 
 
 
Figure 8. Structures of IIb3 antagonists Eptifibatide and 
Tirofiban. 
 
IIb3 antagonists in clinical trials.   All  three 
drugs have undergone extensive clinical trials in the 
clinical setting for the treatment of various coronary 
syndromes  including  percutaneous  coronary  inter-
vention,  myocardial  infarction  and  unstable  angina 
and  non-ST  elevated  myocardial  infarction.  Abcixi-
mab was the first IIb3 targeted platelet antagonist 
to enter clinical trials. Phase I trials established dosing 
regimens and the effects of combination with common 




termined  that  optimal  receptor  occupancy  was 
achieved with single bolus dosing followed with con-
tinuous  infusion.  Weight-adjusted  heparin  dosing 
reduced  the  propensity  for  bleeding  events.  Subse-
quent  large-scale  randomized  trials  examined  the 
impact of abciximab on endpoints such as mortality, 
need for revascularization and occurrence of myocar-
dial infarction [27]. Meta-analysis of the eleven major 
Phase III trials of abciximab showed significant over-
all decreases in death at 30 day endpoint, decreased 
need for revascularization and reduced occurance of 
myocardial infarction in patients receiving abciximab 
during percutaneous coronary intervention, as com-
pared  to  fibrinolytic  agent  in  myocardial  infarction 
and during stent placement for the treatment of un-
stable  angina  [28].  Due  to  possible  immunogencity 
related to the chimeric nature of abciximab, the safety 
of re-administration was examined in the ReoPro re-
administration trial. Abciximab was found to be safe 
for  repeat  administration  [29].  Trials  of  eptifibatide 
were designed in a similar manner as the abciximab 
trials. Phase I studies examined various dosing levels 
alone and in combination with weight-adjusted hepa-
rin. Initially dosing was under estimated as the use of 
citrate anticoagulant chelated calcium ions necessary 
for receptor ligand binding and activation and pro-
duced falsely decreased readings of platelet aggrega-
tion that led to lower than anticipated performance in 
meeting  protocol  endpoints  for  survival,  restenosis 
and  myocardial  infarction  [30-31]. Subsequent  trials 
utilized  anti-coagulants  that  did  not  perturb  meas-
urements of platelet aggregation and dosing was in-
creased from single bolus 135 mg/ kg to double bolus 
180 mg/kg with 2 mg/kg/min infusion for up to 24 h 
[32]. This dosing resulted in significant reduction in 
mortality, restenosis and myocardial infarction when 
used in the ESPRIT trial [33]. The Randomized Effi-
cacy Study of Tirofiban for Outcomes and Restenosis 
(RESTORE) trial evaluated tirofban versus placebo in 
patients at risk for arterial obstruction due to multiple 
acute coronary syndromes and those undergoing an-
gioplasty for myocardial infarction. Significant reduc-
tion  in primary endpoints were noted at day 2 but 
decreased by day 30 [34]. Overall meta-analysis of 12 
trials  of  IIb3  antagonists  in  over  20,000  patients 
demonstrated a significant reduction in mortality and 
myocardial infarction at 30 days [35].  
Factors impacting the therapeutic efficacy of IIb3 
antagonists.   The efficacy of IIb3 antagonists is 
modulated by the total number of receptors available 
for drug binding. It is generally accepted that roughly 
80% of the total platelet  IIb3 integrins  should be 
bound to obtain therapeutic dosing [36]. Platelet count 
is the primary determinant of receptor availability as 
IIb3  integrins  are  expressed  almost  solely  on  the 
surface  of  platelets,  at  levels  of  approximately 
50-100,000 receptors per platelet. Although the in vivo 
significance of platelet count on drug efficacy has not 
been  clearly  established  ex  vivo  studies  suggest  an 
inverse  relationship  between  platelet  count  and  in-
tegrin inhibition [37]. Additional factors that contrib-
ute, albeit less so, to receptor occupancy are the ratio 
of  internalized  receptors  versus  receptors  at  the 
platelet surface, the degree of receptor activation, and 
blood plasma fibrinogen levels.  
Resting platelets  typically  maintain an internal 
receptor  pool  that  upon  activating  stimuli  such  as 
ADP and Thromboxin A2 binding can be externalized 
to increase surface expression by 40-50%. Of this in-
ternalized pool, a portion may emerge at the platelet 
surface  bound  to  soluble  fibrinogen  released  from 
-particles within the platelet. Abciximab is unable to 
completely inhibit this internal pool and the mimetic 
antagonists  as  competitive  inhibitors  may  also  lose 
efficacy, but likely to a lesser degree in light of their 
rapid dissociation kinetics [38]. 
 Bleeding  events  associated  with  the  use  of  IIb3 
antagonists.   As potent antiplatelet drugs, admin-
istration  of  IIb3  antagonists  carry  with  them  the 
risk of adverse bleeding events. Early on, the initial 
clinical  trials  involving  IIb3  antagonists  demon-
strated  an  increased  risk  of  bleeding  complications. 
Evaluation of Abciximab in clinical trials for the pre-
vention of ischemic complications (EPIC trial) during 
angioplasty established the superiority of unfraction-
ated  heparin  administration  combined  with  abcixi-
mab bolus and continued infusion over UFH alone, 
but  also  revealed  a  two-fold  increase  in  bleeding 
complications among the combined treatment group 
[39]. The propensity for bleeding complications was 
recapitulated in the CAPTURE trial, wherein patients 
with  refractory  unstable  angina  were  treated  with 
heparin and placebo or heparin and abciximab [30]. 
To address this significant concern, subsequent clini-
cal trials of abciximab as well as eptifabitde and tiro-
fiban employed weight-adjusted dosing for heparins. 
In doing so, the risks of serious bleeding complica-
tions fell, with  little  or no impact on drug efficacy. 
Despite alterations in dosing, bleeding events remain 
a concern for the use of IIb3 antagonists. The ther-
apeutic  window,  or  the  range  of  plasma  concentra-
tions at which these antiplatelet drugs act in both a 
safe and efficacious manner, is quite narrow and is 
dependent on the number of receptors available for 
drug binding. Drug plasma concentrations that pro-
mote receptor occupancy  below 80% fail to achieve 




greater than 90% receptor occupancy are associated 
with higher risk of adverse bleeding events [40]. 
Drug-induced  thrombocytopenia  following  IIb3 
antagonist treatment.   A  small  percentage  of  patients 
receiving  IIb3  antagonists  experience  thrombocy-
topenia,  a  severe  drop  in  platelet  number  (platelet 
count < 50,000) that is associated with increased inci-
dence of ischemic events, bleeding related complica-
tions  and  requirement  of  plasma  transfusions  [41]. 
The  primary  cause  of  thrombocytopenia  in  patients 
treated with IIb3 antagonists appears to be immune 
mediated  [42],  although  non-immune  mediated 
mechanisms  have  been  reported  for  the 
RGD-mimetics, eptifibatide and tirofiban [43]. Bleed-
ing events can range from minor occurrences such as 
leakage  at  the  site  of  IV  insertion,  to  systemic, 
life-threatening episodes requiring rapid intervention. 
As  a  humanized  chimeric  antibody,  abciximab  has 
demonstrated a propensity for the induction of hu-
man  antichimeric  antibody  response  upon  first  ad-
ministration in approximately 1% of patients and in 
4% upon repeat administration [29]. Thrombocytope-
nia caused by immune-mediated platelet destruction 
following  Abciximab  treatment  may  be  of  rapid  or 
delayed  onset  [44].  Acute  thrombocytopenia  occurs 
within hours of infusion and may be accompanied by 
fever, drop in blood pressure, and anaphylaxis. Rap-
id,  immune-mediated  platelet  destruction  occurs 
through the binding of IgG and IgM antibodies that 
recognize murine sequences of the Fab’ fragment or 
platelet  conformational  changes  induced  by  abcixi-
mab  binding.  Delayed-type  thrombocytopenia  has 
also been noted to occur up to 8 days following cessa-
tion of treatment and may be caused by newly formed 
antibodies or through the stimulation of existent an-
tibodies [45]. The rate of drug-induced thrombocyto-
penia is of lower frequency in patients receiving the 
ligand mimetics, Tirofiban and Eptifabitide compared 
to Abciximab treated patients [46]. The onset is usu-
ally acute, within hours of treatment and can be ac-
companied by symptoms  similar to those accompa-
nying abciximab immune thrombocytopenia. In con-
trast  to  Abciximab,  the  clearance  rate  of  the  RGD 
mimetics is much faster, thus limiting to the time pe-
riod in which patients are at risk of bleeding events 
due to thrombocytopenia. The severity of complica-
tions varies from asymptomatic to minor bleeding to 
major hemorrhage. Immune mediated thrombocyto-
penia is believed to result from the clonal expansion 
of  haptens,  antibodies  that  recognize  drug-bound 
receptors.[44] Monitoring platelet counts prior to and 
following administration of all three platelet inhibi-
tors is warranted considering these issues. Depending 
on  the  severity  of  related  bleeding  events,  platelet 
transfusion may be necessary to restore haemostasis. 
Oral IIb3 antagonists as preventive treatment for 
coronary  syndromes.  Prolonged  inhibition  of  platelet 
aggregation  using  aspirin  and  thienopyredine  has 
been demonstrated to significantly reduce the risk of 
ischemic  events  [47].  It  was  hypothesized  that,  as 
more  potent  inhibitors  of  platelet  aggregation,  the 
IIb3 antagonists would show increased benefit in 
long-term ischemia risk reduction. Based on the suc-
cess and clinical efficacy of the parenterally adminis-
tered IIb3 antagonists, an effort to develop orally 
available small molecule antagonists for the long-term 
prevention of cardiovascular disease was undertaken 
and led to the clinical evaluation of several antago-
nists  having  similar  structural  characteristics  and 
pharmacological properties (Fig. 9). Most of the drugs 
from this class are prodrugs, requiring hepatic con-
version to the active state and having limited bioa-
vailability  in  the  range  of  7-38%  [48].  The  plasma 
elimination half-life for these compounds is generally 
in the range of 4-20 h with the exception of roxifiban 
that has an elimination half-life of up to 5 days. Renal 
excretion  accounts  for  the  primary  means  of  drug 
elimination within this class. Pharmacokinetic studies 
established that efficacious dosing was in the range of 
5-30 mg. Higher doses given once daily were associ-
ated with increased bleeding events, lower more fre-
quent dosing provided similar effect and reduced the 
bleeding  risks.  Renal  insufficient  patients  required 
lower dosages to prevent increased risk of bleeding 
presumably to decreased clearance rates [48]. Despite 
the  dose adjustment efforts taken  in risk reduction, 
the outcomes of dose ranging studies revealed overall 
increase in the risk of bleeding amongst all antago-
nists tested [48]. 
Following the dose-ranging studies, large scale 
randomized,  double-blinded,  placebo-controlled 
Phase III trials of xemilofiban, orbofiban, sibrafiban, 
and lotrafiban were undertaken. None of these studies 
were able to demonstrate decrease in the incidence of 
either short-term or long-term ischemic events. Trials 
of  orbofiban,  sibrafiban  and  lotrafiban  were  termi-
nated  early  due  to  increased  excess  mortality  risk. 
Meta-analysis of 4 Phase III trials carried out in over 
33,000  patients  confirmed  a  31%  increase  in  overall 
mortality associated with the oral platelet antagonists, 
halting  the  inception  of  further  trials  and  develop-
ment [49]. 





Figure 9. Structures of orally active, small molecule IIb3 antagonists. 
 
 
The mechanism leading to increased mortality is 
confounding based on evaluation of the meta-analysis 
of concurrently measured endpoints such as myocar-
dial infarction, need for urgent revascularization and 
major bleeding events. The incidence of myocardial 
infarction was not significantly different between pa-
tients receiving study drug and those receiving aspi-
rin alone. The incidence of urgent need for revascu-
larization  was  significantly  reduced  in  2  of  4  trials 
analyzed,  and  not  significantly  different  in  the  re-
maining two trials [49]. These results suggest throm-
bosis  may  not  be  the  primary  factor  leading  to  in-
creased  mortality.  A  statistically  significant  three 
percent  increase  in  major  bleeding  events  due  to 
platelet inhibition contradicts lack of antagonist effi-
cacy as a contributing factor to increase in mortality.  
Alternate  mechanisms  have  been  proposed  to 
account for the increased mortality observed with oral 
antagonists  including  drug  related  toxicity,  partial 
agonist  activity,  non-platelet  mediated  mechanisms 
and patient inter-variability. No one mechanism has 
been  explicitly  proven  to  account  for  the  increased 
mortality  and  it  is  likely  that  the  cause  is  mul-
ti-factorial. 
IIb3  antagonists  for  the  treatment  of  ischemic 
stroke.  Similar to acute coronary syndromes, inhibi-
tion of platelet aggregation and thrombus formation 
using aspirin has shown benefit in ischemic stroke by 
reducing recurrence and mortatlity, albeit with mod-
est effects. As potent antagonists of platelet aggrega-
tion  and  thrombus  formation,  is  was  expected  that 
IIb3 inhibitors would demonstrate increased bene-
fits  over  aspirin  for  the  reduction  of  stroke  related 
complications. Contrary to expected, meta-analysis of 
several  large  randomized  clinical  trials  failed  to 
demonstrate conclusive evidence supporting the use 
of  IIb3  antagonists  for  the  treatment  of  ischemic 
stroke [50]. Furthermore, a few recent trials have ter-
minated  enrollment  due  to  increased  incidence  of 
intracranial hemmorhage.  
IIb3  antagonists  for  the  treatment  of  sickle  cell 
disease.  Sickle cell anemia is a hereditary disorder in 
which mutation in the -globulin gene gives rise to 
abnormal  hemoglobin  that  disrupts  the  structural 




leading  to  decreased  pliability,  perturbations  in  ion 
balance and increased adhesion and viscosity in blood 
vessels. Sickle cell anemia is characterized by episodes 
of  ischemia-repurfusion  [51],  increased  levels  of  in-
flammatory mediators [52] and abnormal activation of 
granulocytes and monocytes [53]. Activated platelets 
are thought to contribute to the pathology of Sickle 
cell anemia through multiple processes. Activation of 
platelets  increases  endothelial  cell  activation  [54], 
P-selectin  exposure,  the  exposure  and  release  of 
CD40L [55] and it promotes vasoconstriction. Platelet 
released factors increase adhesion of RBC to vascular 
endothelium, promote coagulation [56], induce vaso-
constriction  [57].  Exposure  and  release  of  CD40L 
triggers  immune  and  inflammatory  responses,  trig-
gers  B-cell  proliferation,  increases  the  expression  of 
endothelial cell adhesion molecules and upregulates 
tissue factor. Platelet adhesivity and adhesion is me-
diated through IIb3 integrin as well as granule se-
cretion and procoagulant activity [56, 58]. Blockade of 
integrin IIb3 with eptifibatide, abciximab or tirofi-
ban prevents thrombus formation, prothrombin acti-
vation  and  the  release  of  CD40L  from  activated 
platelets, events which are central to the pathology of 
sickle cell anemia and therefore, may offer benefit in 
the  treatment  of  sickle  cell  anemia.  Phase  I  trials 
evaluating the safety and pharmacokinetics of eptifi-
batide in sickle cell anemia patients in the non-crisis 
state have shown promising results. Eptifibatide ad-
ministered as two 180 mg/kg boluses separated by 10 
minute interval combined with 2 µg/kg/min infusion 
reduced levels of inflammatory cytokines and myo-
globin, a marker of muscle injury. The vasodialotors 
MMP-2 and MMP-9 were increased with eptifibatide 
treatment,  as  was  the  adipokine  leptin.  Eptifibatide 
treatment had no effect on platelet reactivity or ag-
gregate formation. The observed effects of eptifibatide 
were optimal by 6 h and fully reversible as early as 
24h  following  infusion,  suggesting  that  IIb3  an-
tagonist therapy may be beneficial for the treatment of 
the  acute  painful  crises  characteristic  of  sickle  cell 
anemia [59]. 
5. 4 integrins 
4 integrin chains associate with 1 or 7 integ-
rin  family  members,  via  non-covalent  linkages,  to 
form dimers. The 41 integrin, also known as VLA-4, 
Very Late Antigen-4, and CD49d/CD29, is constitu-
tively expressed on the surface of lymphocytes and 
most leukocytes [3]. The primary ligands of 41 are 
endothelial  VCAM1  and  the  extracellular  matrix 
(ECM)  glycoprotein,  fibronectin.  41  interacts  with 
VCAM1 through the QID(40)SPL site in domain 1, in 
which aspartate 40 appears to be essential for ligand 
binding. Interaction with the ECM occurs through the 
LDV  sequence  of  the  connecting  segment-1  (CS-1) 
region of fibronectin. Other 41 ligands have been 
identified,  including  the  acidic  glycoprotein  osteo-
pontin, juntional adhesional molecule B and molecule 
B and mucosal addressin cellular adhesion molecule 
(Mad-CAM) [60]. 
Similarly,  integrin  47  (LPAM,  Lymphocyte 
Peyer’s Patch Adhesion Molecule) is also expressed 
on the surface of lymphocytes and leukocytes. Inter-
actions of this integrin with VCAM-1 and fibronectin 
occur through the same epitope as 41 integrin, alt-
hough  the  47 avidity  for  VCAM-1  is  considerably 
lower than that of 41. In addition, 47 binds the 
mucosal  addressin  cellular  adhesion  molecule  -1 
(MAdCAM-1) expressed on high endothelial venules 
of  gut  mucosal  lymphoid  tissue  such  as  Peyer’s 
Patches and mesenteric lymph nodes, as well as lam-
ina propria venules [61]. 
The 4 integrin family members, 41 and 47, 
function in leukocyte recruitment from the peripheral 
circulation  to  sites  of  inflammation  within  tissue 
[62-63] (Fig. 10A). The local release of chemokines at 
sites of inflammation causes upregulation of 41 and 
47 on the circulating immune cells and adhesion 
molecules such as VCAM and/or MAdCAM, on the 
surface of proximal endothelial cells. Increased adhe-
sion  molecule  density  enhances  the  probability  of 
forming contacts between circulating, immune com-
petent leukocytes and the vascular endothelium. As 
blood  flows,  binding  between  leukocyte  P-,  L-  or 
E-selectin  molecules  and  endothelial  cell  carbohy-
drates or leukocyte 4 integrins and endothelial cell 
adhesion  molecules  (VCAM  or  MAdCAM)  provide 
the initial contacts needed to capture leukocytes trav-
eling through the circulation. The increased cell to cell 
contact  between  leukocytes  and  the  endothelium 
slows the rate of leukocyte travel through the circula-
tion,  a  process  known  as  rolling  adhesion.  The  de-
creased velocity imparted by the initial contact allows 
chemokines on the surface of vascular endothelium to 
bind  G-protein  coupled  receptors  on  the  leukocyte 
surface, transducing an inside-out signal that further 
activates integrins. The high avidity of activated  4 
integrins for their cognate ligands results in firm ad-
hesion  to  the  endothelium.  Firm  adhesion  is  a  re-
quirement for diapedesis, extravasation of leukocytes 
through the endothelium into the ECM. Once leuko-
cytes  extravasate,  4  mediated  interactions  with  fi-
bronectin of the ECM facilitate migration through the 






Figure 10. Mechanism of immune-cell mediated inflammation and its inhibition by 4 antagonists. Left Panel- 4 integrins 
are up-regulated on the surface of activated immune cells. Through contacts with endothelial cell adhesion molecules such 
as selectins and glycoproteins, these cells are captured from the circulation. The intial contacts are strengthened when 4 
integrins make contact with MAdCAM and VCAM on endothelial cells. Extravasation and migration to sites of inflammation 
are mediated in part through 4 integrins. Right Panel- In the presence of 4 antagonists such as natalizumab, firm adhesion 
and subsequent migration are inhibited preventing immune cell infiltration within tissue.  
 
 
The infiltration of leukocytes and lymphocytes is 
central to the pathology of many inflammatory dis-
eases. The 4 integrin family members, 41 and 47 
act both in the formation of initial contacts and firm 
adhesion  and  therefore,  are  key  constituents  in  the 
process of cellular influx to inflamed tissue. Suppres-
sion of 4 integrin binding inhibits cellular migration, 
thereby attenuating the inflammatory response (Fig. 
10B). The therapeutic potential of  4 antagonists in 
the  attenuation  of  inflammatory  response  has  been 
investigated for the treatment of several chronic dis-
eases.  
Multiple Sclerosis (MS) is an autoimmune dis-
ease affecting the central nervous system (CNS). The 
pathology of MS is caused by increased entry of acti-
vated immune cells through the blood-brain barrier 
(BBB) into the CNS. Activated immune cells initiate 
processes of inflammation, edema and demyelination 
leading  to  the  formation  of  acute  CNS  lesions  [64]. 
The progressive accumulation of lesions in the CNS is 
responsible for the debilitating symptoms of MS, such 
as  fatigue,  imbalance,  loss  of  mobility,  sensory 
symptoms, bladder and bowel dysfunction, memory 
loss  and  concentration  deficits,  spasticity,  visual 
problems, pain and sexual dysfunction [65].  
Contacts between circulating immune cells and 
the BBB is an early and critical event in the patho-
genesis of MS. Antibody directed inhibition of 41 
mediated contacts between immunocompetent cells in 
the circulation and VCAM-1 on the vascular endothe-
lium of the BBB has been demonstrated to prevent the 
development and even reverse disease progression by 
preventing  the  infiltration  of  inflammatory  cells 
through the BBB. Targeting 4 integrin mediated cell 
binding to attenuate immune cell migration therefore 
represents  a  significant  means  by  which  to  prevent 
disease progression. 
Crohn’s  disease  and  ulcerative  colitis  are  idio-
pathic  inflammatory  diseases  of  the  intestinal  tract 
characterized by focal or continuous regions of mu-
cosal  inflammation,  respectively,  which  produce 
symptoms  of  abdominal  pain,  diarrhea  and  rectal 
bleeding and over time physical manifestations such 
as  strictures  and  perforations  of  the  intestinal  wall. 
Dysregulated  immune  responses  contribute  to  the 
pathogenesis of both types of IBD causing increased 
infiltration of immune cells into muscosal tissue of the 
gut.  Interactions  between  immune  cell  47  and 
VCAM and MAdCAM-1 on the gut mucosa facilitate 
transmigration and are believed to contribute to the 
pathogenesis of IBD [65]. 
Asthma is a chronic inflammatory disease of the 
lung  characterized  by  increased  infiltration  of  acti-
vated  T-cells  and  eosinophils  resulting  in  broncho-
constriction, airway hyperresponsiveness and airway 
remodeling. Inhibition of T-cell migration via block-
ing of 4 mediated cell interactions may reduce the 
severity of asthma symptoms.  
In addition 4 antagnoists have been explored as 
a  therapeutic  means  of  attenuating  the  lymphocyte 
infiltration into joint synovium that is characteristic of 




tis. The rationale for targeting 4 integrin to modulate 
aberrant  immune  cell  migration  and  activation  is 
supported  by  in  vitro  as  well  as  cell-  and  ani-
mal-based studies. Antibodies that block the function 
of  4  and  1  integrin  chains  decrease  T  cell  and 
monocyte binding to VCAM-1 in frozen sections of 
inflamed  blood  vessels  [66].  Inhibition  of  activated 
T-cell migration across the BBB using 41 blocking 
antibodies  prevented  and  in  some  cases,  reversed 
inflammation-induced  neurological  symptoms  in 
mouse,  rat  and  guinea  pig  models  of  experimental 
autoimmune  encephalopathy.  Similar  results  were 
obtained by blocking the 4 ligand VCAM-1 [67]. In-
hibition of 47 reduces the development of sponta-
neous ulcerative colitis in tamaran monkeys [68] and 
alleviates  inflammation  in  mouse  models  of  colitis 
[69]. Inhibition of the 47 ligand, VCAM-1, produces 
similar results in mouse models of induced colitis [70]. 
Studies using monoclonal antibodies directed toward 
4  integrins  or  VCAM  in  animal  models  of  anti-
gen-induced  asthma  suggest  a  critical  role  for  this 
interaction in disease pathophysiology [71]. Various 
small molecule 4 antagonists have shown efficacy in 
allergen-induced asthma models.  
4  antagonists  for  the  treatment  of  inflammatory 
diseases.  To  date,  there  is  only  one  4  antagonist 
approved by the U.S. Food and Drug Administration 
(FDA). Natalizumab is approved for treatment of re-
lapsing, remitting multiple sclerosis and Crohn’s dis-
ease. Natalizumab is a humanized mouse monoclonal 
antibody  directed  against  the  4  integrin.  Natali-
zumab binds 41 and 47 integrin on the surface of 
circulating T lymphocytes preventing interaction with 
cellular adhesion molecules that facilitate extravasa-
tion and migration from the circulation to tissue. 
Following the administration of 300 mg I.V. bo-
lus Cmax was 110  52 µg/mL. Mean average steady 
state concentrations were between 23 and 29 µg/mL 
and  the  time  to  steady  state  was  24  weeks  after  4 
weeks dosing. The mean t1/2 is approximately 11 days, 
with a volume of distribution of 5.7 and clearance of 
16 ml/hour. Clearance is influenced by bodyweight 
and the presence of neutralizing antibodies, increases 
in both results in a faster rate of clearance. Age and 
sex do not affect the rate of clearance [72-73]. 
Natalizumab underwent a series of clinical trials 
for  the  treatment  of  relapsing-remitting  multiple 
sclerosis, and Crohn’s disease. Natalizumab showed 
remarkable efficacy for the treatment of MS in Ran-
domized clinical trials. 4-integrin blockade resulted 
in  a  decrease  in  the  number  of  CD4+  and  CD8+ 
T-cells,  CD19+  B-lymphocytes  and  CD138+  plasma 
cells in CSF for up to 6 months following treatment 
cessation.[74] Based on measurements of 2-year out-
comes,  natalizumab  decreased  clinical  measures  of 
disease such as relapse rates and the risk of sustained 
disability progression by 68 and 54% respectively and 
reduced MRI based disease measures such as the ap-
pearance of new T2 lesions, new gadolinium positive 
lesions and lowered overall disease burden by 83, 92 
and  18  %  respectively  [75].  The  efficacy  of  natali-
zumab treatment appeared to improve with the dura-
tion of treatment. The difference in clinical and MRI 
measures of disease and progression between treated 
and placebo groups were significantly greater in the 
second year compared to the first. By the second year 
of treatment greater than 35% of natalizumab treated 
patients were free of all disease activity and more than 
40% showed only one measure of disease activity [76]. 
In both highly active disease and non-highly active 
disease subgroups, the proportion of patients free of 
disease  activity  was  significantly  higher  than  mem-
bers  of  the  same  group  that  received  placebo  only. 
Health related quality of life measures relating to pa-
tient perceptions regarding disease status were also 
improved in natalizumab treated patients [77]. Clini-
cal measures of efficacy in Crohn’s disease were ini-
tially  less  significant  than  those  observed  in  the 
treatment  of  MS.  Although  treatment  with  natali-
zumab demonstrated efficacy in disease response and 
remission among a high percentage of treated patients 
in the ENACT 1 and ENACT 2 randomized phase III 
trials, both failed to meet their primary endpoints of 
statistically  significant  reduction  in  disease  activity 
across the total population. However, the follow-up 
trial  ENCORE  was  able  to  demonstrate  disease  re-
sponse and remission in active Crohn’s patients re-
ceiving 300 mg intravenous infusion every two weeks 
over a period of 12 weeks. In this randomized, pla-
cebo  controlled,  phase  III  trial,  51%  of  natalizumab 
treated patients showed response by week 4 after one 
infusion. The percent of patients in response at weeks 
8 through 12 was similar to the initial results, 50% of 
natalizumab treated patients sustained response ver-
sus only 37% of patients receiving placebo [78]. 
The most prevalent side effects reported for na-
talizumab  treatment  are  headache  (38%),  fatigue 
(27%) and infusion reaction (24%) [72]. By far the most 
serious side effect associated with natalizumab is the 
onset of progressive multifocal leukoencephalopathy 
(PML)  [79].  PML  is  a  rare,  life-threatening,  demye-
linating infection caused by the JC virus. A large por-
tion of the general population (~80%) is infected with 
latent JC virus. Active PML infections resulting from 
JC  virus  are  often  seen  immunocompromised  indi-
viduals such as HIV patients. The increased incidence 




to be caused by impaired immune surveillance in the 
CNS as a direct result of 4 inhibition on circulating 
immune cells [80]. The risk of developing PML is be-
lieved  to  increase  with  duration  of  Natalizumab 
treatment and may be hastened in patients receiving 
prior  or  concurrent  immunosuppressive  therapies. 
The incidence of PML is calculated to be 1 case per 
1000  patients  treated  with  natalizumab  for  17.9 
months. To date, 11 cases of PML including 3 fatalities 
have been reported in patients receiving Natalizumab 
either as monotherapy or in combination [79, 81-83]. 
Additional  opportunistic  infections  have  been  ob-
served  in  patients  receiving  natalizumab,  although 
the role of natalizumab in causation is as yet unde-
termined. Infections reported include viral meningitis 
and encephalitis (2), acute cytomegalovirus (2), pul-
monary aspergillosis (2), cryptosporidial gastroenter-
itis (1),  Pneumocystis carinii pneumonia (1), varicella 
pneumonia (1), mycobacterium avium  intracellulare 
complex  pneumonia  (1),  and  Burkholderia  cepacia 
pneumonia  (1).  Values  in parentheses  represent  the 
number of reported cases. In an effort to decrease the 
inherent risks accompanying the obvious benefits to 
MS patients, FDA recommendations suggest the use 
of natalizumab in limited populations including those 
refractory to other therapies or those with particularly 
aggressive disease under strict clinical supervision.  
Because  the  increased  incidence  of  PML  is  be-
lieved to be caused as a direct result of 4 antagonism, 
improvement of the biopharmaceutical properties of 
compounds  targeting  4  integrin  would  therefore 
have no bearing on the likelihood of developing PML. 
Though,  presumably,  a  small  molecule  or  pep-
tidomimetic antagonist could present lower risk; the 
shorter plasma half-life of these molecules compared 
to antibodies would prevent the need for costly and 
invasive  plasma  exchange  procedures  currently  uti-
lized for the removal of natalizumab from the blood in 
the  event  PML  symptoms  are  manifest  [84].  Ulti-
mately,  due  to  the  serious  risks  that  increase  with 
duration of administration, 41 integrin antagonist 
based therapies should be limited for the treatment of 
conditions that are life threatening or do not respond 
to first-line treatments. 
Antagonism  of  VLA-4  may  also  have  implica-
tions  for  fetal  and  embryonic  development. 
Cell-to-cell interactions mediated by 41 integrin are 
critical  to  reproductive  events  such  as  fertilization, 
implantation, placental formation and cardiac devel-
opment.  41  knockout  mice  are  embryonic  lethal 
and  show  disruption  in  placentation,  defects  in  al-
lantois-chorion  fusion,  cardiac  abnormalities,  mal-
formation and hemorrhage. VCAM-1 knockout mice 
show similar defects further supporting the role of 4 
integrins in embryonic development. 
Based  on  animal  studies  of  embryonic  and 
post-natal development it has been deemed that pro-
longed, high dose natalizumab treatment caused no 
developmental defects [85-87]. These results cannot be 
extrapolated  to  other  4  antagnoists.  In  fact,  basic 
teratogenicity assays of several small molecule 41 
antagonists in preclinical development showed vari-
ability  in  propensity  to  cause  defects  (Fig.  11).  The 
teratogenic potential of 41 antagonists appears to 
be related to the affinity state of the integrin to which 
the compound binds. Integrins exist in multiple acti-
vation states wherein ligand binding stability is pro-
portional to the affinity or activation status of the re-
ceptor. Compounds that bind to VLA-4 at both low 
and high affinity states appear carry a greater risk of 
toxicity  and  embryonic  defects  compared  to  com-
pounds  selective  for  the  activated  integrin  [88]. 
Therefore integrin activation state affinity is a major 
consideration for the development of successful clin-
ically useful inhibitors.  
4  antagonists  under  clinical  evaluation. 
MLN-00002 MLN-0002 is a human antibody specific 
for  the  47  integrin  dimer.  In  phase  II  trials, 
MLN-00002  showed  dose  dependent  efficacy  as  in-
duction  therapy for the treatment of active Crohn’s 
disease and ulcerative colitis. Treatment consisted of 
two infusions, at day 1 and 29. Primary endpoint was 
a greater than 70 point decrease in the CDAI (Crohn’s 
Disease Activity Index) score achieved in both stud-
ies. In the phase II trials patients were screened for the 
presence of latent JC virus prior to the administration 
of MLN-0002 and were monitored for signs of PML 
through out the course of treatment [89]. 
Firategrast.  Firategrast  is  a  small  molecule  4 
antagonist developed by Glaxo Smith Kline that has 
recently  completed  Phase  I  clinical  trials  for  the 
treatment of Relapsing, Remitting Multiple Sclerosis. 
This trial evaluated pharmacokinetic parameters fol-
lowing oral administration of 900 mg once daily in 
men and women diagnosed with multiple sclerosis. 
Further Phase II studies have been initiated to evalu-
ate the effect of firategrast on white blood cell counts 
in the cerebrospinal fluid.  
IVL745.   IVL745 (Fig. 11) is a small molecule 
antagonist  of  41  antagonist  that  previously 
demonstrated  efficacy  in  animal  models  of  asthma 
and  airway  inflammation  and  allergen  induced 
bronchoconstriction. IVL745 binds activated 41 and 
is  non-teratogenic  [90].  Orally  administered  IVL745 
has  low  bioavailability  and  absorption  properites, 
short plasma half-life. IVL745 is not highly metabo-




biliary route [91]. These limitations in biopharmaceu-
tical  properties  typify  the  problems  inherent  with 
most small molecule 4 antagonists. Bioavailability is 
improved  when  administered  by  inhalation.  Safety 
studies  in  both  healthy  and  asthmatic  volunteers 
demonstrated tolerability by inhalation at dosing up 
to  20  mg  BID.  Subsequent  trials  in  human  asthma 
patients  failed  to  demonstrate  efficacy  greater  than 
that observed with placebo [92-93] suggesting that the 
role of 4 integrins in asthma and allergen induced air 
inflammation  may  be  more  complicated  or  less  in-
fluential than previously predicted [94]. 
 
 
Figure 11. Small molecule 4 antagonists vary in their propensity for teratogenic effects. IVL984 (potent teratogen), 
HMR1031 (mild teratogen) and IVL745 (non-teratogenic) are structurally similar yet have different teratogenicity profiles. 
The difference is attributed to their affinity for non-activated 4 integrin. Compounds that bind 4 in both activated and 
resting states appear to be more teratogenic.  
6. v integrins 
Integrins v3 and v5 are highly expressed on 
the surface of osteoclasts, angiogenic endothelial cells, 
and some solid tumors. Their antagonism  has been 
explored  for  the  purpose  of  preventing/reversing 
osteoporosis, inhibition of angiogenesis and induction 
of  tumor  regression.  Currently  there  are  no 
FDA-approved antagonists of v3 and/or v5 in-
tegrins on the market, but several compounds have 
shown efficacy in preclinical evaluation and are cur-
rently under evaluation in clinical trials for the treat-
ment  of  malignancies,  rheumatoid-arthritis  and  os-
teoporosis.  
v  integrin  antagonists  as  anti-angiogenic  agents. 
Angiogenesis is the process of neovascularization in 
which new blood vessels sprout from existing ones. 
The ‘angiogenic switch’ is an early event required for 
tumor  progression.  Initially  tumor  growth  is  sup-
ported by nutrients and oxygen derived from proxi-
mal vasculature. As tumor mass increases, local blood 
supply  becomes  inadequate,  resulting  in  a  hypoxic, 
nutrient-deprived tumor environment. The inducible 
transcription factor, hypoxia-ducible factor-1 (HIF-1) 
is  activated  in  response  to  the  local  hypoxic  condi-
tions, leading to the release of trophic factors such as 
vascular  endothelial  growth  factor  (VEGF).  Tumor 
associated macrophages have recently been identified 
as another means by which the angiogenic switch can 
be  tripped.  Tumor-released  cytokines  stimulate  the 
migration  of  macrophage  precursors,  that  once  dif-
ferentiated  in  the  tumor  mass  can  secrete 
pro-angiogenic growth factors and tissue proteases. In 
an autocrine fashion, proliferating tumors cells release 
VEGF, basic fibroblast growth factor (bFGF) and tu-
mor necrosis factor alpha (TNF-). VEGF-receptor 2 
(VEGFR2)  acting  in  concert  with  v5  and 
FGF-receptor  (FGFR)  co-signaling  with  v3  stimu-
late distinct signaling pathways that can be integrated 
to  heighten  the  angiogenic  response.  Growth  factor 
release  stimulates  the  proliferation  of  quiescent  en-
dothelial cells and signals the migration of angiogenic 
endothelial  progenitor  cells  from  the  bone  marrow 
stroma to the tumor bed. v3 and v5 integrins are 
highly expressed on the surface of angiogenic endo-
thelial cells as compared to resting endothelial cells. In 




row-derived  endothelial  cell  progentior  to  terminal, 
committed endothelial cell, v3 integrin expression 
increases. Integrin v3 and v5 recognize the RGD 
sequence  in  ECM  components  such  as  fibronectin, 
fibrinogen,  and  vitronectin.  Through  interactions 
between v3 and v5 integrins and the ECM, mi-
grating endothelial cells are captured from the circu-
lation and participate in the formation of vasculature 
to feed the growing tumor. The association of integrin 
v3 with matrix proteases including matrixmetallo-
protease  -2  (MMP-2),  matrixmetalloprotease-9 
(MMP-9) and urokinase plasminogen activator (uPA) 
facilitates ECM degredation allowing tissue extrava-
sation. Integrins on the leading edge of lamelapodia 
use ECM components to generate the traction neces-
sary for cell migration. Adhesion and spreading are 
mediated  through  integrin  binding  to  ECM. 
Cell-to-cell  contacts  are  mediated  through  integrins 
during tube formation and vessel maturation. During 
angiogenesis integrins stimulate the processes of en-
dothelial cell migration, proliferation, differentiation 
through  FAK/Src/p130Cas  and  Raf/MEK/Erk  sig-
naling pathways [95]. 
Endothelial survival in both nascent and estab-
lished  tumor  vasculature  is  supported  by  integrin 
mediated signaling events that are dependent on li-
gation with the ECM. Integrin ligation promotes cell 
survival primarily through activation of the PI3K/Akt 
pathway.  Cross  talk  between  integrins  and  growth 
factor receptors, possibly through trimeric interaction 
between growth factors, growth factor receptors and 
integrins [96], inhibits the activation of intrinsic and 
extrinsic pathways of apoptosis. In addition, integrin 
ligation  promotes  the  increased  expression  of  the 
pro-survival  molecules  Bcl-2  and  FLIP,  increases 
NFkB  signaling  and  decreases  p53  activation.  Hy-
per-stimulation of pro-survival signaling mechanisms 
aids endothelial cells as they form vasculature in the 
hypoxic  tumor  microenvironment.  Conversely,  un-
ligated integrins can promote apoptosis through the 
interruption of pro-survival signaling and the initia-
tion of pro-apoptotic signaling cascades [6, 97].  
The significance of v3 and v5 integrins in 
the  processes  of  angiogenesis  is  supported  by  a 
wealth of experimental data obtained using in vitro, 
cell culture and in vivo methods. Angiogenic factors 
and tumor-secreted cytokines increase the expression 
of v3 integrin in animal and human models of an-
giogenesis.  Inhibition  of  v3  and  v5  integrins 
prevents endothelial cell migration, adhesion, differ-
entiation, tube formation and survival in cell culture 
models and has been demonstrated to inhibit angio-
genesis and vascular tube formation in animal mod-
els. Mice null of v integrin expression show a high 
rate of embryonic lethality due to bleeding and pla-
cental  defects,  as  do  3  knockout  mice.  Surviving 
v-knockout mice die prematurely due to complica-
tions of vessel malformation in the brain and gut. In 
contrast, surviving 3 knockout mice exhibit normal 
vasculature and increased angiogenic potential, pre-
sumably through up-regulation of VEGFR2 mediated 
compensatory  mechanisms.  The  reasons  for  the 
pro-angiogenic effect of 3 knockdown and the im-
plications for the role of v3 integrins in angiogene-
sis is a source of continued debate. It is important to 
keep  in  mind  that  the  observed  effects  of 
3-knockdown during development may differ from 
those seen post-natally [97-98]. 
The primary goal of anti-angiogenic therapy is to 
prevent tumor growth by inhibiting the formation of 
new  vasculature  and  destroying  established  tumor 
blood vessels that feed oxygen and nutrients to the 
growing neoplasm. Additional evidence suggests that 
anti-angiogenic therapies may act to transiently stabi-
lize  tumor  vasculature  increasing  oxygenation  and 
perfusion. The resulting increase in tumor blood flow 
may explain the seemingly paradoxical potentiation 
in efficacy observed when anti-angiogenic agents are 
combined  with  standard  chemotherapies  [99].  An-
ti-angiogenic agents are generally well tolerated and 
can  be  administered  at  high  doses  with  few 
dose-limiting  toxicities.  With  low  levels  of  toxicity, 
anti-angiogenic agents can easily be combined with 
standard drug regimens with little or no additional 
adverse effects. The anti-angiogenic effects of radia-
tion therapy can synergize with angiogenic inhibitors 
to  increase  cell  kill  [100].  Additionally,  as 
non-transformed cells, the genetic stability of endo-
thelial  cells  precludes  the  development  of  drug  re-
sistance, making them an attractive target.  
v integrin antagonists as anti-tumor agents.   In-
hibition of integrins has demonstrated growth inhib-
itory effect independent of angiogenesis. As in endo-
thelial cells, vb integrins support tumor cell adhe-
sion, proliferation, survival migration and  invasion. 
Integrin v3 is expressed on a variety of cancer cells 
including melanoma, glioma, breast, prostate, cervi-
cal,  ovarian  and  pancreatic  cancers.  Patients  whose 
tumors  express  high  levels  of  v3  tend  toward  a 
poorer  prognosis  than  patients  with  low  tumor  ex-
pression  levels.  Expression  of  v3  integrins  in  tu-
mors is associated with an aggressive phenotype. The 
increased expression of v3 imparts metastatic po-
tential and invasive traits. In some instances, v ex-
pression  increases  during  transition  to  a  metastatic 
phenotype supporting a role for this integrin in me-




between integrins v3 on tumor cells and IIb3 on 
activated  platelets  facilitates  circulating  tumor  cell 
capture  from  the  blood,  a  critical  initial  step  in  the 
metastatic  cascade.  Extravasation,  migration,  adhe-
sion and proliferation are supported by integrin liga-
tion with the extracellular matrix. Association of v3 
integrin  with  Src  promotes  anchorage  independent 
cell  growth.  v3  mediated  signaling  through  focal 
adhesion kinase (FAK) supports the survival of cancer 
stem  cells.  Inhibtion  of  v3  is  associated  with  de-
creased  tumor  cell  growth  in  breast  and  prostate 
cancers, melanomas and gliomas. Supression of tumor 
v3 integrin expression in animal models decreases 
the ability of tumor to migrate and metastasize [6]. 
v integrin antagonists for the treatment of osteopo-
rosis.  Osteoporosis is a disease characterized by the 
progressive loss of bone density due to imbalances in 
the rate of bone resportion by osteoclasts and bone 
formation by osteoblasts. The disease is common in 
post-menopausal  women,  as  age-related  declines  in 
estrogen levels increase osteoclast activity. Osteopo-
rosis  imparts  increased  risk  of  fractures  leading  to 
augmented rates of morbidity and mortality among 
osteoporotic  women  [65].  The  development  of  anti-
resorptive agents that prevent osteoclast function to 
successfully  reverse  bone  loss  and  increase  bone 
mineral  density  (BMD)  are  of  great  interest  for  the 
treatment of osteoporosis. v3 integrins are highly 
expressed on the bone surface and have been impli-
cated in cell spreading, migration and signaling pro-
cesses  central  to  osteoclast  function.  Inhibition  of 
v3 has been demonstrated to prevent bone resorp-
tion both in vitro and in vivo. The RGD-disintegrin, 
echistatin prevents bone loss in hypercalcemic mice 
on a low calcium diet [101]. It also inhibits serum cal-
cium level increases following parathryroid hormone 
treatment in parathyroid/thyroidectomized mice and 
prevents  bone  resporption  in  ovarectomized  mice 
[102-103].  Similarly,  3  function  blocking  antibody, 
mAb F11 blocks the effect of parathyroid hormone on 
blood calcium levels [104]. At the genetic level, dis-
ruption  of  3  induces  late  onset  osteoporosis  in 
knockout mice. Osteoclasts derived from these mice 
are  unable  to  spread,  lack  cytoskeletal  organization 
and  show  decreased  capacity  to  resorp  bone  [105]. 
The exact mechanisms by which v3 integrin inhibi-
tion prevent bone resorption are not clear as the role 
of v3 in osteoclast function are not completely de-
lineated.  In  vitro  studies  suggest  that  v3 antago-
nism prevents bone resorption through inhibition of 
osteoclast migration [106-107]. A few orally available, 
small  molecule  v3  antagonists  have  been  devel-
oped for the treatment of osteoporosis and are in the 
early stages of clinical development.  
Therapeutic antibodies. A series of therapeutic an-
tibodies  targeting  v  integrins  are  currently  under 
development and in clinical trials as antiangiogenic 
and anti-tumor agents. These antibodies are summa-
rized in Table 1.  
Table 1. v3 targeted therapeutic antibodies. 
Antibody  Source  Reactivity  Specificity  Activity  Clinical Development 
LM609  mouse monoclonal  human, rabbit, 
chicken 
αvβ3, αIIbβ3, αvβ5 
dimers 
Blockade of TNFα and bFGF 
induced angiogenesis. Induces 
apoptosis. 
Immunogenicity and hu-
man anti-mouse antibody 
responses preclude its use 
in clinical applications. 
Further modifcations 
produced vitaxin. 
Vitaxin  humanized mouse 
monoclonal derived 
from LM609 
human, mouse  recognizes αvβ3 
dimer 
Blockade of TNFα and bFGF 
induced angiogenesis. Induces 
apoptosis 
Deemed safe in Phase I 







human, mouse  recognizes αvβ3 
dimer 
Blockade of TNFα and bFGF 
induced angiogenesis. Induces 
apoptosis 
In Phase I trials, long term 
safety established; failed to 
demonstrate efficacy. 
CNTO 95  humanized IgG1  human, 
does not recog-
nize murine 
αv integrin specific 
αvβ3, αvβ5 
Inhibits melanoma cell adhesion, 
migration and invasion in vitro. 
Inhibits tumor growth in mouse 
melanoma xenografts 
Phase I trials established 
safety, 1 prolonged re-
sponse observed. Phase II 
trials are underway. 
c7E3  chimeric mouse hu-
man 
human, murine  αIIbβ3, αvβ3, MAC-1 Potenet antiplatelet drug. Shows 
anti-cancer activity in preclinical 
studies. 
FDA approved for treat-
ment/ prevention of 
thrombosis during angio-
plasty and in Acute Coro-
nary Syndromes. Increased 
risk of bleeding events 
may preclude use in cancer 
drug regimens. 
17E6  mouse monoclonal  human, 
does not recog-
nize murine 
αv integrin specific 
αvβ3, αvβ5, αvβ1 
Inhibits tumor growth in αvβ3 
positive tumor xenografts. Ac-
tivity attributed to blockade of 
tumor integrins. 
Immunogenicity and hu-
man anti-mouse antibody 
responses preclude its use 
in clinical applications. 





LM609 LM609 was developed in the laboratory 
of David Cheresh and was subsequently used in the 
discovery  and  characterization  of  v3  integrin  as 
adhesion molecules in endothelial and melanoma cell 
lines. As such it is a mouse monoclonal antibody that 
recognizes human  v3 integrin dimers. It displays 
cross reactivity with cognate rabbit and chicken but 
not murine v3 integrins [108]. LM609 binds v3 
integrin and prevents the adhesion and spreading of 
endothelial cells to ECM proteins fibrinogen, vitron-
ectin,  von  Wilebrand  Factor  mulitmers,  and 
RGD-peptide  coated  surfaces  but  not  collagen  or 
laminin  as  these  interactions  are  mediated  through 
alternate adhesion receptors [98]. LM609 is unable to 
lift attached endothelial cells from the former  men-
tioned ECM components presumably due to epitope 
masking as a result of intergrin interactions with ma-
trix proteins. In cell based models of bone resorption 
LM609  supresses  osteopontin-induced  cytosolic  cal-
cium  reduction  and  subsequent  osteoclast  function 
through the inhibition of v3 signaling [109]. In quail 
embryo  models  of  embryonic  neovasculogenesis, 
LM609 effectively disrupts the process of vessel for-
mation  [110].  LM609  also  inhibits  angiongenesis  in 
mouse-human  skin  graft  tumor  models  [111].  The 
anti-angiogenic  and  anti-tumor  properties  observed 
with LM609 treatment in experimental models occurs 
primarily via the inhibition of v3 mediated TNF 
and bFGF signaling pathways. The murine origin of 
LM-609 limits its clinical utility, raising the concern of 
antigenic  responses  when  administered  to  humans. 
Humanization of LM-609 using phage display strat-
egy produced the second generation v3 antibody, 
Vitaxin.  
Vitaxin  (MEDI-523,  Applied  Molecular  Evolution, 
San Diego, CA) Vitaxin is  the humanized version  of 
LM609 containing the mouse CDR region grafted to 
human IgG1 Kappa. Humanization using phage dis-
play libraries produced greater affinity while retain-
ing epitope specificity and reduced antigenicity [112]. 
In  pre-clinical  evaluation  Vitaxin  inhibited 
growth-factor mediated endothelial cell proliferation 
and prevented angiogenesis. Vitaxin has been evalu-
ated in two Phase I clinical trials for the treatment of 
advanced, treatment refractory solid tumors. The ini-
tial Phase I trial evaluated dosing in range of 0.1 to 4 
mg/kg administered weekly as a 90 minute intrave-
nous infusion over a period of six weeks among 17 
patients. Adverse effects were observed in 88% of the 
patients but were mild and of low grade in the initial 
studies. The most common adverse event was infu-
sion  reaction  including  fever,  nausea  and  chills  but 
preadministration  of  aspirin  and  diphenhydramine 
abrogated  this  effect  and  no  further  reactions  were 
noted  with  pre-treatment.  No  immunogenicty,  an-
ti-vitaxin  antibodies  or  propensities  for  prolonged 
bleeding  or  delayed  wound  healing  were  noted 
among any of the patients. The volumes of distribu-
tion were consistent with that of plasma distribution. 
The low dose regimen of 0.1 mg/kg resulted in plas-
ma  half-life  of  14.6  hours,  while  the  highest  dose 
tested,  4.0  mg/kg  produced  much  longer  plasma 
half-lives  between  63-138  hours.  The  AUC  was  in-
creased  with  dose  but  not  proportionally.  Vitaxin 
treatment resulted in 7 instances of stable disease and 
one partial response. Continued treatment up to 93 
weeks  in  3/17  patients  was  well  tolerated  and  de-
layed disease progression but did not result in tumor 
regression [113]. The second Phase I trial evaluated 
Vitaxin administered as two doses of either 10, 50 or 
200  mg  seperated  by  a  three  week  interval,  with  a 
focus  on  radioimaging  and  gathering  of  pharmaco-
kinetic data for Phase II studies. Vitaxin was admin-
istered as two doses of 10, 50 or 200 mg administered 
at day 0 and 21 as a 90 minute intravenous infusion. 
No toxicity was noted for the lowest dose cohort, the 
most common adverse event in the other cohorts was 
infusion related response such as fever and nausea. 
Grade 3 pain and hepatic toxicity and grade 1 head-
ache were also reported among patients in these co-
horts.  No  anti-vitaxin  antibodies  or  immunogenicty 
was noted in this trial. Pharmacokinetic parameters 
for  the  10  mg  dose  were  not  obtained  due  to  low 
plasma  recovery  following  the  90  minute  infusion. 
Higher doses of vitaxin demonstrated greater plasma 
recovery. Doses of 200 mg produce plasma  half-life 
(t1/2)  of  ~7  days  and  circulating  plasma  levels  of  ≥ 
1mg/ mL, a level consistent with saturation of v3 
receptors in vitro. No tumor response was noted in 
any of the patients in any of the treatment cohorts.  
Two patients in the 50 mg cohort and 1 patient in the 
200  mg  cohort  were  assessed  at  day  43  as  having 
achieved stable disease, received 4 additional doses of 
vitaxin and were taken off study at day 85 with stable 
disease. Two patients in the 10 mg cohort and 1 pa-
tient each from the 50 and 200 mg cohorts were taken 
off study at day 43 due to disease progression. Two 
patients,  one  each  from  the  10  and  200  mg  cohorts 
were removed from study after 1 dose due to disease 
progression. Radio-imaging was not successful due to 
label instability.[114] In general, vitaxin was well tol-
erated  in  patients  even  with  prolonged  administra-
tion.  Pharmacokinetic  data  obtained  suggests  that 
dosing  within  ranges  of  200  to  800  mg  is  likely  to 
produce plasma concentrations consistent with com-




Abegrin  (etaracizumab,  MEDI-522,  MedImmune) 
The absence of objective disease responses seen in the 
vitaxin phase I and II trials was attributed to limita-
tions of affinity and stability in vivo. It was believed 
that improvements in these parameters would result 
in a better therapeutic outcome. Therefore, the epitope 
affinity of Vitaxin was improved using step-wise af-
finity  maturation  producing  the  humanized  mono-
clonal antibody, Abegrin [115]. This antibody main-
tained  specificity  for  v3,  yet  inhibited  binding  to 
vitronectin and fibrinogen  with 7.2 fold greater po-
tency  than  its  predecessors  LM-609  and  Vitaxin. 
Abegrin was highly active in preclinical evaluations, 
preventing cell adhesion, migration, proliferation and 
integrin  mediated  signaling  events  in  a  dose  de-
pendent  manner  at  clinically  achievable  concentra-
tions [115]. Phase I studies evaluated pharmacokinetic 
parameters and angiogenic response in patients with 
advanced stage, treatment refractory neoplasms rep-
resenting a wide spectrum of cancer types with par-
ticular  focus  on  late-stage  colorectal  cancers,  mela-
nomas and lymphomas. Reports of Phase I trials in-
volving  25  lymphoma  and  solid  tumor  patients 
showed dosing in the range of 2-10 mg/kg/ weekly to 
be well tolerated. Pharmacokinetic parameters such as 
peak  and  trough  plasma  concentrations,  Cmax  and 
AUC were increased in a dose dependent manner and 
accumulated with continued dosing such that values 
recorded at week 4 were higher than those observed 
in week 1. Plasma concentration half-life was longer at 
week 4 compared to week 1. There were no significant 
differences in accumulation between doses. No major 
or serious adverse events were recorded and as such 
MTD was not achieved in this study. Antigenicity was 
not observed in any of the treated patients. In total 8 
of 25 patients achieved stable disease at the 8 week 
evaluation. Stable disease was recorded in 4 patients 
with metastatic renal cell carcinoma following 16-95+ 
months on treatment. Although no significant chang-
es  were  observed  in  vascular  area,  endothelial  cell 
proliferation and apoptosis or 3 integrin expression 
levels,  surrogate  measures  of  angiogenic  potential 
were altered in response to Abegrin treatment. Tumor 
blood mean transit time was increased in one renal 
cell  carcinoma  patient  following  treatment,  perhaps 
due  to  decreased  tumor  vascularization  resulting 
from v3 integrin inhibition. Levels of phosphory-
lated Focal adhesion kinase (pFAK) were significantly 
decreased in skin blood vessels following one round 
of  treatment,  suggesting  that  Abegrin  may  act 
through disruption of focal adhesions [116]. 
Abegrin has completed Phase II clinical trials for 
the treatment of multiple cancers, rheumatoid arthri-
tis and plaque psoriasis either as a single agent or in 
combination with clinically relevant drugs. Based on 
results of the Phase II trial of Abegrin in combination 
with the DNA alkylating agent, dacarbazine in meta-
static  melanomas,  in  which  treatment  alone  or  in 
combination did not significantly impact overall sur-
vival,  further  oncology  trials  have  been  suspended 
pending further investigation [117]. 
CNTO95 CNTO95 is a fully humanized antibody 
produced by immunization of transgenic mice carry-
ing  the  human  repetoire  of  immunoglobulins. 
CNTO95  binds  v  integrins  including  v1,  v3, 
v5  and  v6.  CNTO95  binds  purified  v3  and 
v5 with dissociation constants (Kd) of 2.1 and 2.5 
nM respectively and cell-surface v3 and v5 Kd in 
the range of 5- 24 nM [118]. In preclinical evaluation 
CNTO95 showed significant anti-angiogenic and an-
ti-tumor  activity.  CNTO95  prevented  adhesion  and 
migration of human umbilical vein endothelial cells 
(HUVECs) and human melonoma cells plated on the 
v3 and v5 ECM ligands vitronectin, fibrinogen, 
and  fibrin  [118].  In  a  dose  dependent  fashion, 
CNTO95  inhibited  HUVEC  and  human  melanoma 
cell proliferation and inhibited neovascularization in 
both in vitro and in vivo models of angiogenesis [118]. 
In xenograft studies, CNTO95 significantly inhibited 
tumor growth independent of its anti-angiogenic ef-
fect and potentiated the effects of fractionated radia-
tion on tumor growth [119]. CNTO95 distributes sys-
temically and binds v integrin on the surface of both 
normal and neoplastic tissue. Despite systemic tissue 
distribution, no adverse effects were noted after pro-
longed  administration  up  to  6  months  in  macaque 
monkeys [120]. CNTO95 is currently under investiga-
tion in Phase I and II clinical trials as a single agent for 
the treatment of advanced melanomas or in combina-
tion with dacarbazine or avastin for treatment of solid 
tumor or prednisone and docetaxel for treatment of 
metastatic  hormone  refractory  prostate  cancer.  Re-
sults of the Phase I, dose-escalating trials in patients 
harboring  solid  tumors  CNTO  demonstrated  a  fa-
vorable  safety  profile  in  which  infusion  reactions 
controlled  with  acetominophen  appeared  to  be  the 
most common adverse event. Pharmacokinetic analy-
sis of dosing between 0.1 and 10 mg/kg showed rapid 
clearance at lower dosage and non-linear decrease in 
the rate of clearance indicative of tissue binding. Ac-
cumulation upon repeated administration was noted 
only in the two highest dose cohorts (3, 10 mg/kg). 
Analysis  of  a  post-treatment  biopsy  confirmed  the 
presence of CNTO 95 within the tumor cytoplasm and 
decreased expression of bcl-2 following treatment. A 
partial response and stable disease were documented 
in 1 and 6 of 24 patients respectively, although of the 




status.  Following  treatment,  stable  disease  was  rec-
orded for up to seven months [121]. Based on the fa-
vorable  safety  profile,  tissue  distribution  and  inci-
dence of partial response, Phase II trials will be pur-
sued further.  
c7E3 (Abcixmab)  c7E3 is currently approved by 
the  FDA  for  treatment  of  multiple  acute  coronary 
syndromes,  for  use  in  percutaneous  coronary  inter-
vention and myocardial infarction and has been re-
viewed  for  these  purposes  in  a  previous  section. 
Abciximab recognizes v3 integrin with nearly the 
same affinity as IIb3 and for this reason may also 
have anti-angiogenic and antitumor activities. In ad-
dition through the inhibition of  IIb3 on platelets, 
Abciximab may have anti-metastatic activity by pre-
venting  the  adhesion  of  v3  adhesion  competent 
tumors to platelet thrombi.  
RGD-based peptides Integrins v3 and v5 bind 
cellular  adhesion  molecules  through  the  interaction 
with RGD-containing recognition motifs found within 
endogenous  ligands  such  as  vitronectin,  fibrinogen 
and  fibronectin.  The  first  peptide-based  pharmaco-
logical antagonists of the v3 integrin were protein 
fragments based on the RGD-sequence. These flexible 
linear  peptides  lacked  integrin  specificity  and  were 
susceptible to proteolytic degradation in vivo making 
them unsuitable for drug development. Structure ac-
tivity  relationships  based  on  thoughtful  chemical 
modifications proved to be quite informative in the 
development  of  more  potent,  selective  and  biologi-
cally  stable  peptide  drugs.  Cyclization  of  the  RGD 
peptide and addition of D-amino acids created steric 
constraints to better mimic the spatial orientation of 
the  natural  ligand  while  simultaneously  protecting 
against  enzymatic  hydrolysis  thereby  increasing 
binding affinity and biological stability. Variations in 
peptide length (i.e. penta- versus hexa- peptides) were 
found  to  alter  integrin  selectivity.  Introduction  of 
D-isoforms  and  N-methylation  of  RGD-  flanking 
amino acids was found to increase binding affinity. 
Cilengitide, a cyclic RGD peptide clearly exemplifies 
the  effects  cyclization  and  amino  acid  modification 
impart  on  receptor  specificity  and  peptide  stability. 
Cilengitide binds integrin v3 4 times more potently 
than  cRGDfV,  a  cyclic  pentapeptide  containing 
D-phenylalanine  and  362  times  more  potently  than 
the straight chain peptide GRGDSPK [122].  
Cilengitide (EMD 121974, Merck) Cilengitide (Fig. 
12) is a cyclic pentapeptide containing the RGD se-
quence,  D-phenylalanine  and  N-methyl  valine,  de-
noted c-[Arg-Gly-Asp-DPhe-(NMeVal)] (Fig. 12). It is 
a  potent,  selective  inhibitor  of  integrins  v3  and 
v5. In solid phase receptor binding assays the IC50 
for inhibition of integrin v3 and v5 binding to 
vitronectin  are  0.58  nM  and  37  nM  respectively. 
Cilengitide  shows  considerably  lower  affinity  for 
other  integrins,  with  IC50  concentrations  10-  to 
100-fold higher in receptor binding assays. These dif-
ferences in IC50 concentration among the various in-
tegrins are indicative of the selectivity of cilengitide 
for  v3  and  v5.  Cilengitide  binds  the 
RGD-binding  cleft  of  integrins  v3  and  v5  ob-
structing adhesion to the extracellular matrix and in-
hibiting  integrin  mediated  cell-cell  interactions.  The 
EC50 for cell attachment varies with cell type but is 
generally in the high nanomolar to low micromolar 
range for both v3 and v5. By inhibiting integrin 
binding, cilengitide attenuates integral cellular func-
tions that are mediated through adhesion, cytoskeletal 
organization  and  intracellular  signaling  pathways 
[123]. 
Cilengitide  has  shown  promising  potential  for 
therapeutic development based on preclinical studies. 
In contrast to the therapeutic antibodies targeting v 
integrins currently in clinical evaluation, cilengitide is 
able to lift matrix-adherent cells, and does so at con-
centrations similar to that inhibiting cell attachment. 
Thus, by competitive inhibition, cilengitide may offer 
increased benefit by targeting both nascent and estab-
lished  tumor  vasculature.  Additionally,  cilengitide 
has shown anti-cancer activity in cell lines and animal 
models  that  express  v3  and  v5  integrins.  The 
interactions between tumor cells and angiogenic en-
dothelium  are  complex  and  thus  experimental  evi-
dence has not clearly delineated the interplay between 
these two cell types. 
In  cell  culture  models,  cilengitide  attenuates 
growth, proliferation and survival in endothelial cells 
and tumor cells expressing v3 and v5 integrins 
by preventing interactions between integrins and the 
extracellular  matrix.  Cilengitide  inhibits  endothelial 
cell migration, attachment and spreading on vitron-
ectin at low micromolar concentrations. Similar effects 
have  been  noted  following  cilengitide  treatment  in 
v3, v5 positive glioma [124], breast [125], mela-
noma [126] and non-small cell lung cancer cell lines 
[127]. Following cilengitide treatment, endothelial and 
glioma  cells  show  disruption  of  actin  organization 
and  tight  junction  formation  consistent  with  inhibi-
tion  of  cytoskeletal  organization  [128].  Cilengitide 
inhibits cell signaling through FAK-Src-Akt and Erk 
mediated  pathways  in  endothelial  and  tumor  cells 
and  attenuates  the  effect  of  VEGF  stimulation  on 
growth factor signaling [129]. At sublethal concentra-
tions,  cilengitide  inhibits  the  NFkB  component, 
p65Rel-A in U251 glioblastoma cells [100]. Cilengitide 




activity in vivo. In several cases, the tumor sensitivities 
and drug combinations that have been determined in 




Figure 12. Structures of v3 antagonists in clinical development. 
 
In  chick  chorioallantoic  membrane  (CAM)  as-
says,  injection  of  cilengitide  into  CAM  vasculature 
prevented  the  growth  of  implanted  U87MG  glioma 
and DAOY medulloblastoma tumor fragments com-
pared to the inactive peptide EMD135981. The inhibi-
tion  of  tumor  growth  was  attributed  to  the  an-
ti-angiogenic  activity  of  cilengitide  as  membrane 
vascularity surrounding the tumor graft was greatly 
decreased by cilengitide treatment as compared to the 
inactive  control  peptide  [130].  In  animal  models, 
cilengitide, as a single agent effectively inhibited the 
growth and proliferation of orthotopically implanted 
malignant glioma and medulloblastoma cell lines in 
nude mice. Daily treatment of established xenografts 
with 100-200 µg cilengitide significantly delayed tu-
mor  growth  and  prolonged  survival  compared  to 
controls.  The  delayed  tumor  growth  was  accompa-
nied by increases in CD31 and tumor doubling times, 
elevated apoptotic index and decreases in prolifera-
tive  index  and  tumor  vessel  number  and  density 
[130]. Interestingly, the efficacy of cilengitide as a sin-
gle agent appears to be limited to brain tumors, as 
results have reported a modest effect of cilengitide on 
melanoma,  breast  and  lung  cancer  xenografts  [100, 
125, 127]. The disparity in the anti-angiogenic effects 
of  cilengitide  may  be  dependent  on  the  microenvi-
ronment in which a tumor resides as parallel hetero-
topic and orthotopic implantation of identical glioma 
cell  xenografts  exhibit  differential  sensitivities  to 
cilengitide treatment [130].  
Radiation  therapy  has  been  demonstrated  to 
have effects on tumor vasculature in addition to its 
direct cytotoxic effects on tumor cells. Interestingly, 
studies  have  shown  that  radiation  can  increase  the 
expression of integrin v3 up to two fold in endo-
thelial cells as well as breast and lung cancer cells. In 
vitro  and  in  vivo  studies  have  shown  benefit  from 
combination  of  radiation  therapy  and  cilengitide 
treatment. In cell based assays combination of radia-
tion and cilengitide treatment enhances cell detach-
ment,  inhibits  endothelial  cell  tube  formation,  de-
creases cell proliferation and increases apoptosis. In a 
human breast cancer xenograft tumor model, combi-
nation of radioimmunotherapy (RIT) with cilengitide 
resulted in radiation dose dependent increase of cure 
rate  from  15%  (RIT  alone)  to  53%  (RIT  plus  cilen-
gitide) at 260 µCi [125]. A more recent study using 
U251  human  glioma  cells  showed  that  cilengitide 
blocked tumor cell adhesion in vitro with no effect on 
responses of these cells to radiotherapy. In contrast, 
cilengitide  strongly  amplified  radiation  effects  on 




to prolonged survival (50 days from control, 110 days 
radiation only, and >200 days combination of cilen-
gitide and radiation) along with enhanced apoptosis 
and  suppressed  tumor  growth.  The  synergism  was 
determined  to  be  highly  schedule  dependent,  as  a 
single dose of cilengitide (4 mg/kg) given between 4 
and 8 hour prior to radiation was required to produce 
this effect. Dosing at shorter and longer time periods 
failed to prolong survival [100].  
Based on preclinical animal models, cilengitide 
has  been  demonstrated  to  synergize  with  the  DNA 
alkylating  agent,  temozolomide  in  malignant  mela-
noma. Combination of 100 mg/kg/day temozolomide 
with 40 mg/kg/day cilengitide significantly inhibits 
B16 melanoma growth compared to control or cilen-
gitide treated mice. This effect was accompanied by 
low overall toxicity suggesting potential clinical ap-
plication [126-127]. 
Phase I trials of cilengitide in solid tumors and ma-
lignant gliomas. Cilengitide has been evaluated in six 
open-label, Phase I trials with the intent to establish 
safety  and  pharmacokinetic  profiles,  determine 
maximal tolerated dose and optimal biological dose 
and correlate responses with potential angiogenic and 
genomic  biomarkers.  The  initial  two  trials  enrolled 
adult patients with advanced stage solid tumors re-
fractory to conventional treatment or lacking stand-
ardized  therapy  [131-132].  Two  subsequent  trials 
evaluated cilengitide in adults with various types of 
malignant glioma [133] and in children with refrac-
tory brain tumors [134]. Phase I trials in patients with 
locally advanced or metastatic cancers and Kaposi’s 
sarcoma have been completed, but results have not 
been  released.  Phase  I  studies  in  patients  with  ad-
vanced  solid  tumors  or  lymphomas  are  currently 
underway. 
 In  the  first  phase  I  study,  cilengitide  was  ad-
ministered  parenterally  at  doses  between 
30-1600mg/m2 twice weekly in 37 patients with solid 
tumors [132]. In the subsequent Phase I trial of cilen-
gitide in patients with advanced solid tumors, 20 en-
rollees received similar infusions at doses of 600 and 
1200 mg/m2 for up to 50 courses [131]. The Phase I 
trials  in  adults  with  recurrent  gliomas  enrolled  51 
patients and followed similar treatment schedules as 
previous trials. Dose escalation was performed in the 
range of 120-2400 mg/m2 [133]. The pediatric study 
followed  similar  dose  escalation  protocols,  with  35 
patients  receiving  cilengitide  infusions  between 
120-2400 mg/m2 [134]. 
In each of the four Phase I trials reported, cilen-
gitide was administered as a 1-hour intravenous in-
fusion  at  doses  between  30  and  2400  mg/m2 twice 
weekly, in 4- week cycles up to 50 cycles. Pharmaco-
kinetics were similar amongst all trials including the 
pediatric glioma trial. Serum pharmacokinetics estab-
lished a linear relationship between dose and AUC 
and Cmax. The terminal half life (t1/2) was between 2.5 - 
4  hours.  Kinetics  is  dose  independent  and  time  in-
variable. Systemic clearance, volume of distribution at 
steady state (Vss) and t1/2 were not significantly dif-
ferent  between  dose  levels  or  following  prolonged 
administration (day 1 compatred to day 15). The Vss is 
in line with distribution within the interstitial space as 
it correlates with the extracellular fluid volume. Sys-
temic clearance is low compared to measurement of 
the rate of renal and heptic blood flow. Dose per body 
surface area did not affect clearance suggesting flat 
dosing was possible. Pharmacokinetic parameters are 
not  affected  by  concurrent  use  of  enzyme  inducing 
anticonvulsants.  Peak  plasma  concentrations  at 
120mg/m2 infusion of cilengitide reached the optimal 
concentration that inhibited tumor growth in preclin-
ical models, but the short plasma half-life favors the 
adjustment of dose to obtain continuous exposure.  
In  the  initial  Phase  I  studies  of  cilengitide  ad-
ministered  to  patients  with  solid  tumors  as  single 
treatment at dosing up to 2400 mg/m2 intravenously, 
twice  a  week  for  at  least  4  consecutive  weeks, 
dose-dependent  toxicity  and  dose  limiting  toxicity 
(DLT) were not observed [131-132]. However, in the 
Phase  I  trial  of  cilengitide  in  adults  with  recurrent 
malignant glioma several grade 3 and 4 DLTs, possi-
bly related to treatment were observed [133]. These 
DLTs  included  thrombosis,  joint  and  bone  pain, 
thrombocytopenia, anorexia, hypoglycemia, and hy-
ponatremia,  but  were  limited  to  one  occurence  per 
cohort.  Grade  3  and  4  toxicities  possibly  related  to 
study drug were noted in the pediatric glioma trials as 
well [134]. At doses of 2400 mg/m2, 3 of 13 pediatric 
patients developed intratumoral hemorrhage, two of 
which were asymptomatic and would under current 
standard be classified as Grade 1 or 2. These events 
were not considered dose limiting since their occur-
rence at days 44-157 post inception, was outside the 
timeframe of DLT observance. Other observed toxic 
effects of cilengitide treatment were mild to moderate 
in severity and similar amongst all studies. These ef-
fects included grade 1 to 2 fatigue, nausea, and head-
ache, vomiting and anorexia. The toxicities were not 
dose-dependent and did not require dose reduction. 
In general, treatment was well tolerated, with mild to 
moderate toxicity (Grade 1 and 2 only) reported at all 
dose levels in three of four trials and a limited number 
of  DLTs  in  the  adult  glioma  trial.  For  this  reason, 
definition of maximum-tolerated dose (MTD) was not 




Although patient response to treatment is not a 
primary  endpoint  in  Phase  I  trials,  Cilengitide  as  a 
signle agent did exhibit promising results particularly 
in the glioma patients. In trials of Cilengitide in adults 
with  recurrent  gliomas  2  complete  responses  were 
noted at doses of 360 and 2400 mg/m2 following 12 
and 24 months of treatment. Remission was sustained 
up to 29 and 15 months post-treatment in these pa-
tients. In addition partial responses were recorded for 
three patients  with a mean duration of 9.3 months. 
Stable disease was achieved in 16 patients for a mean 
period of 5.4 months. Of these patients, 4 sustained 
progression free survival for up to 29 months follow-
ing  Cilengitide  treatment.  The  responses  seen  with 
Cilengitide in pediatric patients with refractory brain 
tumors appeared hopeful as well. One complete re-
sponse was achieved at 1200 mg/m2 dosing following 
one year of treatment, with improvement in clinical 
symptoms sustained up to one year. In total six in-
stances  of  stable  disease  were  also  associated  with 
Cilengitide treatment in this trial. Two patients com-
pleting one year of treatment sustained stable disease 
up  to  22  weeks.  Three  patients  were  evaluated  as 
having  stable  disease  following  the  second  4-week 
treatment  cycle  based  on  MRI  results  but  failed  to 
meet  all  protocol  criteria  for  stable  disease.  There 
were no complete responses recorded for any patient 
in the trials of cilengitide for the treatment of refrac-
tory or advanced solid tumors. Taken together there 
were seven instances of stable disease ranging in du-
ration from 4-15 months in duration associated with 
Cilengitide treatment [133]. 
Evaluation  of  endothelial  cell  proliferation 
markers,  tumor  and  endothelial  cell  apoptosis  and 
adhesion molecule expression failed to demonstrate 
correlates  between  patient  response  and  the  an-
ti-angiogenic activity of cilengitide [131-133]. Correla-
tion studies for serum angiogenesis factors, including 
P-selectin, I-CAM, V-CAM-1, VEGF, bFGF, systemic 
angiogenesis factors, endothelial cell apoptosis, gene 
expression  profiles  and  tumor  tissue  mean  vessel 
density, all showed no correlation or no reliable cor-
relation with response or predicted anti-tumor activ-
ity  except  for  a  modest  increase  of  P-selectin  over 
time.  Use  of  MRI  to  measure  tumor  perfusion  de-
tected  slight  differences  between  responders  and 
non-responders but could not be fit with pharmaco-
dynamic modeling. Decreased tumor perfusion was 
associated with higher cilengitide dose. The failure to 
establish  correlates  between  biological  markers  and 
tumor response is not surprising, as the lack of ex-
perimentally  validated  biomarkers  for  the  measure-
ment  of  anti-angiogenic  activity  is  a  major  impedi-
ment for the development and evaluation of agents of 
this type.  
Interactions  with  cytochrome  P450  and 
P-glycoprotein family members can alter drug expo-
sure levels and duration, significantly impacting drug 
efficacy and toxicities. Concommitant administration 
of enzyme inducing or inhibitory drugs and popula-
tion-wide differences in genetic constitution are two 
common factors affecting enzyme activity. Combina-
tion of cilengitide with cytochrome P450 enzyme in-
ducing anticonvulsants  had no effect on  pharmaco-
kinetic parameters suggesting that this family of drug 
metabolizing enzymes may not have a great impact 
on treatment [133]. Pharmacogenetic analysis of single 
nucleotide  polymorphisms  (SNPs)  in  the 
P-glycoprotein isoform ABCB1 in 15 pediatric patients 
receiving  cilengitide  suggests  that  SNPs  in  exon  26 
may alter renal and overall clearance [134]. Further 
study in larger populations is warranted. 
Overall  assessment  of  Phase  I  trials  demon-
strated  that  Cilengitide  treatment  is  well  tolerated 
across a wide range of doses, with few serious toxici-
ties. Dosing in the range of 120-360 mg/m2 appears 
sufficient to achieve plasma concentrations similar to 
those determined experimentally to be sufficient for 
anti-tumor  activity,  with  higher  dosing  associated 
with response to treatment. The lack of serious tox-
icity  suggests  that  cilengitide  could  easily  be  com-
bined with conventional chemotherapies and targeted 
anti-cancer agents for improved results. In these pre-
liminary evaluations, Cilengitide showed promise for 
the treatment of gliomas, a subset of cancers with poor 
prognoses that are notoriously difficult to treat. Taken 
together, the positive results obtained in Phase I trials 
have  led  to  the  design  and  implementation  of  nu-
merous Phase II trials of cilengitide as both a single 
agent and in combination with cytotoxic and targeted 
therapies for the treatment of brain tumors, prostate 
cancer, melanomas, pancreatic cancer and lung can-
cer.  
Phase II studies of cilengitide as a single agent and in 
combination. At least five Phase II trials of cilengitide 
as  a  single  agent  have  been  completed  and  several 
others  are  ongoing.  Trials  currently  underway  are 
evaluating cilengitide as a single agent for the treat-
ment  of  metastatic  melanoma,  progressive  and  re-
current  glioblastoma  multiforme,  recurrent  glioma 
and localized and metastatic prostate cancers. Results 
of  trials  in  glioblastoma  multiforme  and  asympto-
matic,  androgen-independent  prostate  cancer  have 
been reported and show modest response rates.  
The results of a multi-center, randomized Phase 
II trial examined response to flat dosing in glioblas-




previous cycles of standard treatment. In this trial, 81 
patients were randomized to receive dosing of either 
500 or 2000 mg infusions of cilengitide twice weekly 
for up to 48 weeks [135]. In addition to evaluation of 
safety and efficacy profiles, this trial compared plas-
ma  and  cerebrospinal  fuid  (CSF)  pharmacokinetic 
parameters to evaluate the efficiency of drug delivery 
to the tumor site. Plasma pharmacokinetic parameters 
were similar to those observed in Phase I trials. Cmax 
and  AUC were linear and dose dependent  with no 
accumulation  over  prolonged  administration.  Drug 
accumulation  was  confirmed  in  the  cerebrospinal 
fluid. CSF drug concentrations were dose dependent 
and  maximal  concentrations  were  found  to  be  ap-
proximately 100 fold less than those observed in the 
plasma. The CSF time to Cmax was delayed 2 h com-
pared to plasma Cmax with elimination half-life up to 
two  fold  longer.  No  complete  responses  were  ob-
served  in  this  trial,  although  7  patients  achieved  a 
partial  response.  Progression  free  survival  was 
mainted  for  10-36  months  amongst  all  responders. 
Grade  3-4  toxicities  were  infrequent  and  limited  to 
hematological origin. None of the treatment groups 
achieved  statistical  significance  in  the  defined  end-
points of 6 months progression free survival, overall 
survival,  radiologic  response  or  quality  of  life 
measures. Patients in the 2000 mg treatment cohort 
did tend to have higher response rates as measured by 
radiologic response, media overall survival and pro-
gression free survival. The endpoint of 6 month pro-
gression free survival  was met in a median 15% of 
patients in the 2000 mg cohort compared to 10% from 
the 500mg group. The overall survival (OS) was 9.9 
months in the 2000 mg cohort versus 6.5 months in the 
500 mg cohort. A higher percentage of patients in the 
2000 mg cohort completed 12 or more treatment cy-
cles, but the percentage of patients completing 24 cy-
cles was the same. In the 2000 mg treatment group 
13% of the patients completed >12 treatment cycles as 
compared  to  7%  in  500  mg  treatment  group.  The 
number of patients receiving ≥ 24 cycles was 5% in 
both  treatment  groups.  The  overall  response  rates 
were  deemed  to  be  similar  to  those  observed  with 
temozolomide  treatment  suggesting  that  for  the 
treatment of glioblastoma multiforme, cilengitide may 
act  more  potently  when  combined  with  standard 
therapies.  
Preliminary results of a randomized Phase II trial 
of cilengitide as a single agent treatment for asymp-
tomatic,  androgen-independent  prostate  cancer 
showed modest effects, with a failure to meet the 6 
month primary endpoint, a predicted rate of 75% de-
lay in progression based on historical controls [136]. 
Patients randomized to receive flat dosing of 500 or 
2000  mg  infusions  twice  weekly  in  6-week  cycles 
showed 6 month progression free survival rates of 14 
and 27%, respectively. Stable disease was observed in 
27% and 36% of patients in the 500 and 2000 mg co-
horts. Analysis of biological markers failed to estab-
lish  correlates  between  treatment  response  and 
marker  expression.  Bone  markers  did  not  demon-
strate  significant  correlation  with  response  and  the 
number  of  circulating  tumor  cells  was  increased  in 
both treatment groups as  disease progressed. As in 
past  trials,  treatment  was  well  tolerated.  Toxicities 
were limited to Grade 3 and lower in both treatment 
groups. Based on the lower than hypothesized impact 
on outcomes, further enrollment was halted.  
In Phase II trials as a single agent, cilengitide was 
well  tolerated  and  displayed  uniform  pharmacoki-
netic parameters amongst studies. Cilengitide is able 
to penetrate the blood brain barrier and accumulate in 
the CSF following treatment, a critical determinant for 
therapeutic delivery. Response rates, progression free 
survival  and  overall  survival  were  moderate  when 
adminstered  as  a  single  agent  in  both  glioblastoma 
multiforme and androgen-independent prostate can-
cer patients. The  utility of cilengitide appears more 
evident for the treatment of glioblastoma multiforme 
as current treatment modalities fail to produce signif-
icant  remission  rates  or  even  delays  in  progression 
and no standard therapy currently exists in the likely 
event  of  recurrance.  Under  these  circumstances, 
treatments that offer even modest response warrant 
further development.  
Phase  II  trials  of  cilengitide  in  combination  with 
standard therapies Angiogenesis is a complex process 
and  current  evidence  suggests  that  combination  of 
anti-angiogenic agents with cytotoxic and/or targeted 
drugs may be necessary for complete growth inhibi-
tion.  Furthermore,  preclinical  studies  demonstrate 
that  Cilengitide  sensitize  tumor  cells  to  radiation 
treatment  which  on  its  own  has  also  shown  an-
ti-angiogenic effects. Cilengitide has a favorable safety 
profile over a wide range of doses and modest effects 
as  a  single  agent  suggesting  the  combination  with 
cytotoxic  and  targeted  drugs  and/or  radiotherapy 
would be a feasible approach to improve treatment 
modalities.  To  this  end,  numerous  studies  have  in-
vestigated the effects of Cilengitide when combined 
with treatment regimens for pancreatic and non-small 
cell lung cancer, squamous cell carcinoma of the head 
and  neck  and  glioblastoma  multiforme.  Results  of 
trials in glioblastoma multiforme and pancreatic can-
cer have recently been reported.  
Combination of cilengitide and gemcitabine. Survival 
rates for pancreatic cancer are historically low. In pa-




vival times are 6-10 months. Advanced disease sur-
vival  times  are  roughly  half  that  of  early  stage  pa-
tients.  Gemcitibine  has replaced 5-fluoruracil as the 
standard of care for advanced disease, but improved 
treatment and regimens are still  needed to increase 
overall  survival  rates.  In  a  recent  multi-national, 
open-label,  controlled,  randomized  Phase  II  pilot 
study with advanced stage pancreatic cancer patients, 
combination of cilengitide with gemcitibine failed to 
demonstrate  a  difference  in  outcome  compared  to 
treatment with gemcitibine alone despite the signifi-
cant role of angiogenesis in pancreatic tumor growth 
[137]. A total of 89 patients were enrolled and ran-
domized  to  receive  600  mg/m2  cilengitide  as  intra-
venous infusion twice weekly in 4 week cycles com-
bined with 1000 mg/m2 gemcitibine administered as 
intravenous infusion weekly for 3 weeks followed by 
one  week  rest  or  a  similar  schedule  of  gemcitibine 
alone. Study protocol defined the primary endpoint as 
overall survival and secondary endpoints of progres-
sion free survival, response rate and quality of life. 
CA19.9 served as a biomarker of disease progression 
and plasma VEFG and bFGF levels were evaluated as 
markers of angiogenic response. The combination of 
gemcitibine and Cilengitide was well tolerated and no 
influence of gemcitibine on Cilengitide pharmacoki-
netic parameters was detected. The number of cycles 
of treatment received and the duration of treatment 
was  similar  amongst  both  groups.  Quality  of  life 
measures  were  not  significantly  different  between 
groups.  The  combination  of  gemcitibine  and  Cilen-
gitide did not change the overall rate of survival. With 
the single agent mean survival was 7.7 months com-
pared to 6.7 months when combined with cilengitide. 
The progression free survival times were similar with 
median PFS 3.8 with gemcitibine and 3.6 months in 
the  combination  group.  CA19.9  plasma  levels  in-
creased with disease progression as expected and no 
relationship  between  VEGF  and  bFGF  and  disease 
response  could  be  established.  Combined  treatment 
with cilengitide and gemcitibine could be safely ad-
ministered to patients with no need for dose adjust-
ment  but  failed  to  demonstrate  benefit  over  gem-
citibine alone. Based on these results, it is unlikely that 
cilengitide  would  benefit  pancreatic  cancer  patients 
either alone or in combination.  
In constrast to the less than significant results of 
combined  gemcitibine  and  cilengitide  treatment  in 
pancreatic  cancer  patients,  a  case  report  details  the 
partial  remission  of  an  advanced,  refractory  squa-
mous cell carcinoma of the head and neck following 
combined cilengitide and gemcitibine treatment in a 
single patient [138]. This patient, in the fourth relapse 
with a 15cm diameter squamous cell carcinoma orig-
inating from the upper left jaw, was treated with 600 
mg/m2 cilengitide twice weekly in combination with 
1000 mg/m2 gemcitabine at day 1 and 8 every three 
weeks  for  5  months  and  achieved  partial  response 
with  improved  functionality  and  quality  of  life 
measures. The patient maintained stable disease for 12 
months on cilengitide maintenance therapy with no 
bleeding side effects. The squamous cell carcinoma in 
this case report was highly vascularized making it a 
good candidate for antiangiogenic therapies. Prior to 
combined treatment with cilengitide and gemcitibine, 
treatment  with  gemcitibine  alone  failed  to  stabilize 
disease in this patient. Therefore, unlike trials in pan-
creatic cancer, some benefit was seen with combina-
tion of gemcitibine and cilengitide in this iindividual 
case study.  
Combination of cilengitide and radiation therapy and 
temozolomide.  The  addition  of  cilengitide  to  radio-
therapy and temozolomide based treatment regimens 
has shown promising preliminary results in ongoing 
Phase II trials in both newly diagnosed and progres-
sive glioblastoma multiforme [139-140]. In addition to 
the Phase II objectives sought, these trials are signifi-
cant in that they represent progress that has made in 
determining tumor drug uptake and in identifying a 
subset of patients that may benefit from treatment. In 
a Phase II trial enrolling 52 patients with newly di-
agnosed  glioblastoma  multiforme  receiving  500  mg 
cilengitide twice weekly during radiotherapy and in 
combination with temozolomide for 6 monthly cycles 
following radiotherapy, 69% achieved 6 months pro-
gression free survival compared to 54 % of patients 
receiving  radiotherapy  followed  by  temozolomide 
alone. The one-year overall survival was 67 and 62 % 
of patients for the cilengitide combination group and 
the  radiotherapy  and  temozolomide  group,  respec-
tively.  Non-hematological  grade  3-4  toxcities  were 
limited, and included symptoms of fatigue, asthenia, 
anorexia,  elevated  liver  function  tests,  deep  vein 
thrombosis and pulmonary embolism in across a total 
of 5.7% of the patients. Grade 3-4 hematological ma-
lignancies  were  more  common  and  included  lym-
phopenia  (53.8%),  thrombocytopenia  (13.4%)  and 
neutropenia (9.6%). This trial is significant in the fact 
that is has provided the first evidence correlating a 
molecular biomarker with response to treatment. De-
creased  methylguanine  methyltransferase  (MGMT) 
expression  was  associated  with  favorable  outcome. 
Patients harboring increased MGMT promoter meth-
ylation  appeared  to  benefit  more  from  combined 
treatment  with cilengitide than did patients lacking 
promoter methylation. The significance of the MGMT 




due  to  inclusion  of  temozolomide  in  the  treatment 
combination.  
A similar Phase II study evaluating safety and 
differences  in  overall  survival  among  newly  diag-
nosed  glioblastoma  multiforme  patients  receiving 
radiation therapy combined with temozolomide and 
varying  doses  of  cilengitide  is  nearing  completion. 
Preliminary reports specify that initial safety run-in 
studies in 18 patients receiving doses 500, 1000 and 
2000 mg cilengitide found no dose limiting toxicities. 
Subsequently 94 patients were randomized to receive 
standard  therapy  plus  500  or  2000  mg  cilengitide. 
Median  survival  time  in  both  cohorts  was  18.9 
months. At 12 months the overall survival was 79.5 % 
(89/112 patients).  
Delivery of ciengitide across the blood brain barrier.  
Passage across the blood brain barrier is necessary for 
effective drug delivery to brain neoplasms and suc-
cessful  treatment  requires  the  accumulation  of  ade-
quate amounts of drug at the tumor site. A Phase II 
trial  of  cilengitide  in  combination  with  surgical 
debulking  demonstrated  intratumoral  drug  levels 
following presurgical administration of drug. In this 
trial carried out by the North American Brain Tumor 
Consortium,  30  glioblastoma  multiforme  patients 
with up to two previous progressions were random-
ized to receive 3 doses of 500 or 2000 mg cilengitide in 
the 8 days prior to surgical debulking [140]. Following 
surgery both groups received 2000 mg cilengitide on a 
twice  weekly  dosing  schedule.  Mean  intratumoral 
cilengitide concentrations 24 hours after the last dose 
were 919 ng/g and 2561 ng/g of tissue for 500 or 2000 
mg  doses,  respectively.  Based  on  the  intratumoral 
cilengitide concentration tissue to plasma ratios were 
calculated to be 1.83 for the 500-mg dose and 4.17 for 
the 2000-mg dose. This study effectively demonstrates 
that  cilengitide  can  be  delivered  across  the 
blood-brain barrier and remain at the tumor site for at 
least 24 hours. 
Based on these results, numerous additional tri-
als of cilengitide as a single agent and in combination 
with standard therapies are currently underway, in-
cluding one Phase III trial of cilengitide in combina-
tion  with  radiotherapy  and  temozolomide  in  glio-
blastoma  multiforme  patients  with  methylated 
MGMT gene promoter status. Further Phase II trials of 
cilengitide in combination with standard therapy for 
glioblastoma  multiforme  are  underway  to  evaluate 
the significance of promoter methylation in treatment 
response. Additional trials are evaluating the safety 
and  efficacy  of  cilengitide  when  combined  with 
standard  treatments  for  non-small  cell  lung  cancers 
and squamous cell carcinomas of the head and neck.  
RGD-containing disintegrins. The disintegrins are 
low  molecular  weight  peptides  derived  from  snake 
venoms, more specifically pit viper venoms. The dis-
integrins are classified into three classes, the  RGD-, 
KTS and MLD- based disintegrins. The classification 
is based on ligand mimetic motifs distributed within 
their  disulfide-rich  primary  sequences.  The 
RGD-based members are the most studied disinteg-
rins  and  have  been  investigated  for  their  ability  to 
inhibit angiogenesis and tumor growth and osteopo-
rotic bone loss via blockade of RGD- liganded integ-
rins. The RGD disintegrins bind with high affinity and 
specificity  through  an  RGD-sequence  to 
RGD-dependent  integrins  and  thereby  block  their 
function. At least six separate disintegrins have been 
isolated and characterized for their RGD binding af-
finity. Although the disintegrins are highly effective 
in binding and inhibiting integrin function, their util-
ity in clinical applications is limited due to the prob-
lems of immunogenicity and lability common to pep-
tide-based drugs and the limited supplies typical of 
natural  products.  Efforts  have  been  undertaken  to 
reduce the immunogenicity of disintegrins using ap-
proaches  such  as  targeted  drug  delivery.  Recombi-
nant DNA technology has been employed to produce 
large  quantities  of  disintegrin.  Liposomal  prepara-
tions of recombinant contortrostatin have been shown 
to reduce the growth of MDA-MB-435 breast cancer 
xenografts in nude mice. 
L000845704 L000845704 (Merck) (Fig. 12) is the 
first  small  molecule  v3  antagonist  to  progress 
through clinical trials for the treatment of osteoporo-
sis.  Incorporation  of  RGD-like  pharmacophoric  fea-
tures on a chain shortened, imidazolidine core scaf-
fold produdced L000845704, a selective, potent inhib-
itor of v3 with favorable pharmacokinetic proper-
ties,  lowered  plasma  protein  binding  affinity  and 
good  oral  bioavailability.  In  scinitillation  proximity 
assay the IC50 of v3 binding is 0.08 nM. L000845704 
shows  at  least  100  fold  lower  affinity  for  integrins 
v5  and  IIb3.  In  preclinical  animal  models 
L000845704  was  efficacious  in  modulating  clinically 
relevant  measures  of  osteoporosis.  Ovarectimized 
female  rats,  administered  L000845704  at  10  and  30 
mg/kg/day over a period 28 days exhibited respec-
tive  8.9  and  12.8%  (p  values  <  0.0002)  increases  in 
measures of bone mineral density compared to vehi-
cle treated counterparts. L000845704 increased bone 
mineral density above baseline as effectively as, the 
antiresorptive,  alendronate  in  growing  young  male 
rats (18.4 versus 20.5%, p values < 0.0002). The urinary 
marker of bone degredation crosslinked n-telopeptide 




monkeys following two weeks 15 mg/kg/ day oral 
dosing of L000845704 [141].  
The favorable results in preclinical animal mod-
els led to the advancement of L000845704 into Phase I 
clinical trials. Dosing at 400 mg daily over a two-week 
period in post menopausal women was well tolerated 
and  produced  significant  decreases  in  urinary 
n-telopeptide  crosslinks  suggesting  antiresorptive 
activity. Short plasma half-life prompted the evalua-
tion of varied doses and schedules to optimize evalu-
ation of efficacy and safety parameter in the subse-
quent study. In this large scale, multicenter, random-
ized,  double  blind,  placebo  controlled  12  month 
study, 227 post-menopausal women received 2 week 
open  label  calcium  carbonate,  hydroxy  vitamin  D 
run-in therapy followed by randomization to either 
100 mg qd, 400 mg qd, 200 mg bid or placebo treat-
ment groups. 100mg was deemed the minimum effect 
dose and 400 mg was chosen on the premise that it 
would provide serum levels similar to those found to 
be necessary for efficacy in animal models. The 200 
mg bid was chosen to evaluate its ability to provide 
higher serum trough concentrations. All active treat-
ment groups  met the primary endpoint of decrease 
from baseline in serum and urine n-telopeptide cross-
link/creatine levels. No dose response was seen, and 
maximal decrease was achieved following two weeks 
treatment and maintained for 22 more weeks at simi-
lar levels in all treatment groups. A slight increase in 
levels was noted at 24 weeks but an overall decrease 
up to 42% was maintained through 52 weeks treat-
ment. Serum collagen I n-telopeptide crosslinks (cTx) 
decreased in a manner similar to urinary telopeptides 
with  the  initial  decrease  after  two  weeks  treatment 
with sustained suppression. At the end of 52 weeks 
treatment  cTx  levels  were  decreased  42.2,  46.6  and 
48.4% over baseline. Markers of bone formation in-
cluding osteocalcin and serum bone specific alkaline 
phosphatase steadily decreased following treatment, 
stabilizing after 24 weeks. This effect was in-line with 
other antiresorptive agents tested clinically. The sec-
ondary  endpoint  of  increased  lumbar  spine  bone 
mineral density was met in all three treatment groups. 
Increases of 2.1, 3.1 and 3.5% were noted in the 100 mg 
qd, 400 mg qd and 200 mg bid treatment groups re-
spectively  (p  values  <  0.001)  In  the  remaining 
measures of total hip and femoral neck bone mineral 
density the 200 mg bid treatment appeared superior 
to other treatment levels. Total bone mineral density 
increased in all treatment groups and in the placebo 
group as well. In safety evaluations, L000845704 was 
well tolerated. No drug-related serious adverse events 
were recorded. Minor adverse events were headache, 
decreased  appetite  and  hot  flashes.  Overall, 
L000845704  met  the  endpoints  set  forth  in  clinical 
protocol and exhibited a favorable safety profile. 200 
mg bid dosing appears superior to 400 mg adminis-
tered once daily [142]. 
SB273005 SB273005 (Fig. 12) is an orally active 
small  molecule  antagonist  of  v3  that  has  shown 
efficacy in preclinical animal models. SB273005 binds 
strongly to v3 and lesser degree to v5. It is selec-
tive  against  IIb3  and  51.  Inhibtion  of  v3  by 
SB273005 prevented in vivo bone loss in rat models of 
estrogen  deprivation  mediated  bone  loss  [143].  As 
prophylactic  or  therapeutic  agent,  it  also  prevented 
and reduced edema and inflammation associated with 
arthritis in rat models of rheumatoid arthiritis.  
7. 51 integrin antagonists 
51  integrin  antagonists  are  currently  under 
development for the treatment of cancers, retinal ne-
ovascularization  in  Age-related  Macular  Degenera-
tion (AMD). 51 integrin expression is up-regulated 
in  endothelial  cells  during  angiogenesis  and  is  ex-
pressed on tumor cells’ surface. Ligation of 51 in-
tegrins promotes cell growth and migration through 
the activation of Akt and MAPK mediated signaling 
pathways. Inhibition of  51 integrin binding to fi-
bronectin  prevents  angiogenesis  and  induces  endo-
thelial cell apoptosis.  
Volocixmab Volociximab is the first 5b1 antago-
nist to progress to clinical development. It is a chi-
meric human-mouse monoclonal antibody with high 
affinity for the 51 integrin. Volociximab binds hu-
man 51 integrin with a Kd of 0.32 nM and the ho-
mologous rabbit integrin with a Kd of 7.24 nM [144]. It 
is not reactive with mouse  51 integrin [145]. The 
IC50 for inhibition of human 51 binding to fibron-
ectin is 0.15 µg/mL. Through inhibition of 51, vo-
lociximab  induces  cell  death  and  prevents  capillary 
tube formation in cell based assays. The lack of addi-
tive anti-proliferative effect in endothelial cells when 
combined  with  VEGF  blocking  antibody  led  to  the 
belief  that  volociximab  inhibition  of  51  is  down-
stream, and therefore independent of growth factor 
stimulation. Volociximab has shown both anti-tumor 
and anti-angiongenic activity in animal models. An-
giogenesis  and  tumor  growth  were  diminished  in 
CAM models following volociximab administration. 
In cynomolgus monkey models of choroid vasculari-
zation, volociximab prevented angiogenesis. In rabbit 
VX2  carcinoma  xenograft  models,  10  mg/kg  vo-
lociximab prevented the growth of newly implanted 
as well as established tumors over a three week peri-
od. In the rabbit xenograft studies response to treat-




differences  in  serum  levels  were  attributed  to  the 
presence of rabbit anti-chimeric responses. Increased 
levels  of  serum  anti-volociximab  antibodies  were 
noted in animals less responsive to treatment [145]. 
Volociximab was well tolerated in Phase I trials, pa-
tients with refractory solid tumors dosed with 0.15-15 
mg /kg for up to 104 infusions showed no dose lim-
iting  toxicities.  The  most  common  toxicities  noted 
included nausea, fatigue, headache and athraligia and 
myaligias; all were low grade. The incidence of an-
ti-chimeric  antibodies  and  neutralizing  antibodies 
was low, occurring in 14.3% of patients. One minor 
response was noted in a renal cell carcinoma patient. 
Stable disease was confirmed in five patients for pe-
riods lasting 4-14 months [146].  
In  subsequent  Phase  II  trials,  volociximab 
showed a similar safety and tolerability profile and 
demonstrated  promising  potential  efficacy  in  pro-
longing disease progression and overall survival. In a 
Phase II trial involving patients with metastatic clear 
cell  renal  cell  carcinoma,  10  mg/kg  IV  infusion  of 
volociximab  delayed  disease  progression  up  to  22 
months. Overall survival was 68% at 22 months and 
stable disease was achieved in 80% of patients. An-
other Phase II trial of evaluated volociximab 10 mg/ 
kg every two weeks in combination with 1000 mg/m2 
gemcitibine on days 1, 8 and 15 in 20 male patients 
with metastatic pancreatic cancers. Toxicities included 
nausea, vomiting and constipation. Overall  survival 
was 5.4 months and median time to progression was 
4.3 months. Partial response was noted in one patient 
and  stable  disease  was  confirmed  in  10  patients. 
Combination of 10 mg/kg volociximab with dacarba-
zine 1 g/m2 every four weeks resulted in stable dis-
ease in 22/40 patients with metastatic melanoma. One 
partial response was also observed [147]. 
Additional Phase II and III trials involving vo-
lociximab as a single agent and in combination regi-
mens  are  currently  underway  for  the  treatment  of 
metastatic melanoma, non-small cell lung cancer and 
peritoneal cancer. Phase I trials in non-small cell lung 
cancer in combination with carboplatin and paclitaxel 
have  been  terminated  as  have  Phase  II  trials  in 
metatstatic melanomas and renal cell carcinomas and 
platinum  resistant  ovarian  cancer.  Phase  I  trials  of 
volociximab for the treatment of macular degenera-
tion have also been initiated.  
JSM6427 JSM6427 is a small molecule antagonist 
selective for 51 integrin. It is currently under eval-
uation in a Phase I clinical trial in patients with neo-
vascular  age-related  macular  degeneration.  This 
study will establish pharmacokinetic, safety and tol-
erability  profiles  for  JSM6427  following  single  and 
repeated intravitreal injection of dosing in the range 
of 1.5 to 15 mg/mL. The basis for clinical develop-
ment  is  supported  by  preclinical  evidence  demon-
strating a role for 51 antagonists as a therapeutic 
intervention  to  inhibit  neovascularization.  JMS6427 
induces  HUVEC  apoptosis  and  inhibits  fibron-
ectin-induced Erk phosphorylation in ARPE cells both 
in  a  dose  dependent  fashion.  In  a  mouse  model  of 
choroidal neovascularization induced by laser dam-
age to the retina, continous infusion of JSM6427 in-
duced endothelial cell apoptosis and prevented cho-
roidal  neovascularization  in  established  lesions  at 
dosing between 1.5 and 10 µg/h. Intravitreal injection 
failed  to  produce  similar  results  in  newly  acquired 
lesions suggesting that inhibition of neovasculariza-
tion  by  JSM6427  requires  sustained  plasma  drug 
concentrations [148].  
8. Conclusion 
In the last two decades great progress has been 
made in the discovery and development of integrin 
targeted therapeutics. Years of intense research into 
integrin function has provided an understanding of 
the potential applications for the treatment of disease. 
Advances  in  structural  characterization  of  integ-
rin-ligand  interactions  has  proved  beneficial  in  the 
design and development of potent, selective inhibitors 
for a number of integrins involved in platelet aggre-
gation, inflammatory responses, angiongenesis, neo-
vascularization and tumor growth.  
The  IIb3  integrin  antagonists  were  the  first 
inhibitors to make their way into clinical use and have 
proven to be effective and safe drugs, contributing to 
the reduction of mortality and morbidity associated 
with  acute  coronary  syndromes.  Interestingly,  the 
prolonged administration of small molecules target-
ing this integrin for long-term prevention of throm-
bosis related complications have not been successful, 
for  reasons  that  are  not  yet  fully  understood.  This 
suggests that modulating the intensity, duration and 
temporal  aspects  of  integrin  function  may  be  more 
effective than simply shutting off integrin signaling in 
some instances. Further research into the dynamics of 
platelet  activation  and  thrombosis  formation  may 
elucidate the  mechanisms  by which integrin activa-
tion is modulated.  
The introduction of  4 targeted therapies  held 
great promise for the treatment of inflammatory dis-
eases. The development of Natalizumab greatly im-
proved  the  quality  of  life  for  multiple  sclerosis  pa-
tients and those suffering with Crohn’s Disease com-
pared to previous treatments, but the role in asthma 
related inflammation could not be validated. Unfor-
tunately for MS and Crohn’s patients, immune sur-




compromised as a direct effect 47 antagonism, with 
potentially lethal effects. Thus Natalizumab and re-
lated 47 targeting drugs are now limited to patients 
refractory to standard therapies. The design and de-
velopment  of  41 antagonists  for  the  treatment  of 
Crohn’s  Disease  may  offer  benefit  with  decreased 
risks. The involvement of these integrins in fetal de-
velopment also raises concerns for widespread clini-
cal use.  
Integrin antagonists that target angiogenesis are 
progressing  through  clinical  trials.  Cilengitide  has 
shown  promising  results  for  the  treatment  of  glio-
blastomas and recurrent gliomas, cancers with noto-
riously  low  survival  and  cure  rates.  The  greatest 
challenge facing the development of anti-angiogenic 
integrin  targeted  therapies  is  the  overall  lack  of  bi-
omarkers by which to measure treatment efficacy.  
Overall, the road to clinical application has been 
marked with both success and failure and sometimes 
unexpected results as we find that integrin function 
may  be  more  complex  and  intricate  than  once  be-
lieved. 
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